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1. LITERATURE OVERVIEW 
1.1. G protein-coupled receptors 
Various extracellular signals (chemical or physical) can initiate a chain of bio-
chemical reactions inside the cell by interacting with membrane proteins called 
receptors. The largest family of membrane receptors are G protein-coupled 
receptors (GPCRs), which can transmit extracellular signals into cells mainly 
via G protein activation. Human GPCRs (about 800) are divided into five sub-
families based on their amino acid sequence and structure, among which the 
rhodopsin family is the largest (about 700) (Fredriksson et al. 2003; Wacker et 
al. 2017). These receptors consist of seven hydrophobic transmembrane α-
helices, which are interconnected by intra- and extracellular loops. The recep-
tors can have highly variable structures that allow the binding of specific 
ligands. Ligands are various extracellular signals, including hormones, neuro-
transmitters, toxins and drugs.  
GPCRs regulate a wide spectrum of essential functions in the human body, 
and dysfunctions in their signalling are involved in a number of diseases. Thus, 
GPCRs are important drug targets for the pharmaceutical industry. Structural, 
ligand binding, and functional studies of GPCRs provide valuable information 
for understanding their signalling mechanisms and for the development of new 
drugs. The discovery of cellular signal transduction via G proteins and the 
studies of GPCRs have led to two Nobel Prize nominations, one in physiology 
or medicine to Alfred G. Gilman and Martin Rodbell (1994) and one in 
chemistry to Robert J. Lefkowitz and Brian K. Kobilka (2012). Although drug 
development has been successful in the case of many GPCRs, there are still a 
lot of receptors where the discovery of approved drugs has failed despite great 
efforts. 
 
1.1.1. G protein-coupled receptors as signal transducers 
Signal transduction is the process where a cell receives an extracellular signal 
and transmits it into the cell (Rodbell et al. 1971). A signal-stimulated membrane 
receptor activates a chain of biochemical reactions that produces a secondary 
signal or a change in the activity of a particular protein inside the cell.  
The signal transduction process of GPCRs is usually regulated by the ligand 
binding to the receptor. The specificity of this signal transduction process is 
achieved by the complementarity between the ligand and the receptor. The 
signal transduction is mediated by the conformational changes of the receptor. 
For simplicity, the conformational changes of the receptor have been often 
described by conformational selection (CS) or induced-fit (IF) mechanism (Leff 
1995; Castillo and Katz 1957). Based on the CS model, ligands bind preferen-
tially (with higher affinity) to the receptor in a particular conformational state 
(active or inactive). Whereas, based on the IF model, ligand induces a particular 
conformational state of the receptor after the binding. Although, the ligand 
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binding process is likely much more complicated and consists of several steps 
of conformational adjustments (Meyer-Almes 2016). It has been shown that the 
receptor can undergo different conformational adjustments depending on the 
ligand (Nygaard et al. 2013). 
Ligands are divided into two main categories based on the ligand binding 
site of the receptor – orthosteric ligands and allosteric ligands or modulators 
(Neubig et al. 2003). Orthosteric ligands bind to the active binding site of  
the receptor, and allosteric ligands bind to a topographically different, but 
conformationally linked recognition domain of the primary binding site. 
Allosteric ligands can usually modulate (activate or inhibit) the binding of an 
orthosteric ligand by altering the conformation of the orthosteric binding site of 
the receptor upon binding. Whereas in case receptor multimers are formed, 
cooperativity between the receptor binding sites can add another level of 
sophistication to the ligand binding process (Meyer-Almes 2016).   
Ligands can also be divided based on the effect that ligand binding has on 
the receptor function. The three main categories are receptor activity enhancing 
agonists, non-altering antagonists, and reducing inverse agonists. The effect of 
ligand binding is determined by the level of constitutive/basal activity of 
receptors (Kenakin 2005; Bond and IJzerman 2006). The constitutive activity is 
the receptors’ capacity to induce agonist-independent signalling. Elevated basal 
activity is required for antagonists to act as inverse agonists (Chai et al. 2003). 
Increasing number of GPCRs have shown the ability to exhibit increased basal 
activity in vitro (Costa and Cotecchia 2005; Coll 2013), but its mechanism is 
not yet fully understood.  
GPCRs signalling is commonly mediated through the intracellular hetero-
trimeric G-proteins. Heterotrimeric G proteins consist of three subunits: α sub-
unit, and tightly bound β and γ subunits (Hepler and Gilman 1992). In response 
to agonist binding or due to the constitutive activity, GPCRs associate with 
guanine nucleotide-binding proteins (G proteins) and acts as guanine nucleotide 
exchange factors. In the inactive state of the G protein trimer, guanosine 
diphosphate (GDP) is bound to the α-subunit. Upon activation, G proteins 
undergo conformational changes that lead to the release of GDP from the α-
subunit and the subsequent binding of guanosine triphosphate (GTP). This 
results in further conformational changes that lead to the dissociation of the G 
protein from the receptor; and dissociation of the GTP-bound α-subunit from 
the βγ-complex. The released G protein components can interact with and 
regulate different effector systems, including ion channels and enzymes that 
generate second messengers. The end of the G protein activation cycle is 
marked by the GTP hydrolysis to GDP and subsequent reunification of the α-
subunit and the βγ-complex (Milligan and Kostenis 2006). 
The heterotrimeric G proteins are divided into four families based on the α-
subunits: Gαs, Gαi/o, Gαq/11, and Gα12/13 (Gilman 1987). Depending on the 
family, signalling is conveyed through different pathways (Kristiansen 2004; 
Landry et al. 2006; Birnbaumer 2007). The Gαs activates and Gαi/o inhibits the 
membrane-bound enzyme adenylyl cyclase (AC) that stimulates the production 
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of cAMP (3’,5’-cyclic adenosine monophosphate) from ATP (adenosine tri-
phosphate). Subsequently, the level of cAMP modulates the activity of protein 
kinase A (PKA) pathway. Gαq/11 family activates the membrane-bound enzyme 
phospholipase Cβ (PLCβ), which can lead to the subsequent activation of pro-
tein kinase C (PKC) and Ca2+ release. Gα12/13 family can modulate the activity 
of monomeric G proteins, PKA, or PKC pathways. Importantly, GPCRs can 
have preferential binding to some type of G proteins, but often they are able to 
couple to different types of G proteins. 
 
 
1.1.2. Melanocortin-4 (MC4) receptors 
Five melanocortin receptor subtypes (MC1-MC5) that belong to the rhodopsin 
class of GPCRs were cloned in 1990s (Cone 2000). Melanocortin receptors are 
one of the smallest GPCRs in size consisting of about 300 amino acid residues. 
These receptors are attractive for drug development companies and researchers 
as they play a key role in the regulation of multiple important functions in the 
human body (Wikberg and Mutulis 2008). All melanocortin receptors, except 
the MC2 receptors, have been shown to exhibit high constitutive activity in vitro 
(Coll 2013). It is unique, however, that their constitutive activity is regulated 
not only by endogenous peptide agonists but also by endogenous protein anta-
gonists that can act as inverse agonists in case of elevated basal activity (Chai et 
al. 2003; Coll 2013). 
The human MC4 receptor was cloned in 1993 (Gantz et al. 1993), and its 
crystal structure has been recently solved (Yu et al. 2020). This 332 amino acid 
long receptor has the closest sequence homology to human MC3 receptors (over 
50%). The MC4 receptors are mainly expressed in brain and spinal cord but 
have also been found in the periphery (Wikberg et al. 2000; Abdel-Malek 2001; 
Chaki and Okuyama 2005). MC4 receptors are able to couple to different G 
protein families (Gαs, Gαi/o, and Gαq/11), but they are also able to couple to the 
potassium channel Kir7.1 independently of G proteins (Tao 2010; Asai et al. 
2013). Whereas, most of the earlier studies were directed at the Gαs stimulated 
cAMP production as the indicator for MC4 receptor activation. In addition to the 
cAMP signalling pathway, the MC4 receptors are also able to activate the 
mitogen-activated protein kinase (MPAK) signalling pathway and increase 
intracellular calcium concentration. The MC4 receptors are involved in the 
regulation of several physiologically important functions, whereas their effects 
on eating behaviour and energy homeostasis have been most studied (Wikberg 
and Mutulis 2008). Activation of the MC4 receptors has been shown to increase 
energy expenditure (accelerate metabolism) and reduce food intake. MC4 
receptor ligands are potential drugs for obesity, cachexia, sexual dysfunction, 
addiction, mood disorders, and neuropathic pain (Wikberg and Mutulis 2008; 
Tao 2010). Despite great efforts done so far, there is still a need for thera-
peutically approved drugs for MC4 receptors (Ericson et al. 2017). Recently, 
bremelanotide (Vyleesi™) for MC4 receptors was therapeutically approved for 
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the treatment of premenopausal women with hypoactive sexual desire disorder 
(HSDD) (Dhillon and Keam 2019). The United States Food and Drug Admi-
nistration (FDA) has also just accepted (in May 2020) a new drug application of 
MC4 receptor agonist setmelanotide for the treatment of monogenic and 
syndromic obesity (Kühnen et al. 2016; Clément et al. 2018). 
 
 
1.1.3. MC4 receptor ligands and modulators 
The first experiments demonstrating the in vivo effect of melanocortin peptides 
were performed as early as the 1950s (Shizume et al. 1954), paving the way for 
the isolation and characterization of melanocyte-stimulating hormones (MSHs). 
Melanocortin peptides are among the first purified and sequenced biologically 
active peptides. The hypothesis that larger peptides may act as precursors to 
smaller forms led to the discovery of proopiomelanocortin (POMC), a precursor 
molecule of melanocortin peptides (Nakanishi et al. 1979). The melanocortin 
peptide agonists α-, β-, γ- and δ-MSH and adrenocorticotropic hormone 
(ACTH) are obtained by post-translational treatment of POMCs with prohor-
mone convertases (Cone 2000). All endogenous melanocortin receptor agonists 
contain a conserved His-Phe-Arg-Trp sequence (also called the core sequence), 
which is necessary for the binding to and stimulation of melanocortin receptors. 
The melanocortins that bind to the MC4 receptor are α-MSH, β-MSH, γ-MSH, 
and ACTH (Cone 2000). The melanocortin system is unique among GPCRs as 
it has two endogenous antagonists: agouti protein (also called the agouti signal-
ling protein, ASIP) in the periphery and agouti-related protein (AgRP) in the 
central nervous system (Lu et al. 1994; Ollmann et al. 1997). Whereas AgRP is 
an MC4 receptor antagonist. Both antagonists have shown to behave as inverse 
agonists for melanocortin receptors in case of elevated constitutive activity 
(Haskell-Luevano and Monck 2001; Nijenhuis et al. 2001; Chai et al. 2003). 
Several active peptides and non-peptides have been synthesized in the search 
for ligands that are selective for melanocortin receptors. Peptide agonists, 
aliphatic NDP-α-MSH (also called melanotan I) and cyclic melanotan II (MTII), 
are derivatives of α-MSH, which bind with high affinity to melanocortin 
receptors and have increased stability (Sawyer et al. 1980; Al-Obeidi et al. 
1989). For both of the synthetic agonists, L-phenylalanine amino acid residue in 
the core sequence was replaced with D-phenylalanine amino acid residue. Non-
peptide agonist have also been found for MC4 receptors, such as the small, 
potent, and selective tetrahydroquinoline derivative THIQ (Sebhat et al. 2002). 
Replacement of D-phenylalanine with a hydrophobic D-3-(2-naphthyl)alanine 
amino acid residue in the cyclic MTII led to the discovery of the high affinity 
MC4 receptor antagonist SHU9119 (Hruby et al. 1995). Synthesis of several 
disulfide α-MSH analogues, such as HS024 (Kask et al. 1998), has led to the 
discovery of selective high affinity MC4 receptor antagonists. 
Different physiological metal ions have shown to act as modulators of the 
signal transduction of multiple GPCRs (May et al. 2007; Westhuizen et al. 
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2015). Ca2+ ions are critical cofactors for the high affinity ligand binding to 
MC4 receptors and for the agonist-induced signalling in Gs protein and Kir7.1 
potassium channel pathway (Kopanchuk et al. 2005; Veiksina et al. 2010; Yu et 
al. 2020). These ions have also found to be essential for the signalling of other 
melanocortin receptor subtypes (Salomon 1990; Kopanchuk et al. 2005; Mazina 
et al. 2012). Whereas Zn2+ and Cu2+ ions have been shown to inhibit the ligand 
binding to MC1 and MC4 receptors, while their role in the signalling of the 
receptors has remained inconclusive (Holst et al. 2002; Lagerström et al. 2003). 
In one case, it was reported that Zn2+ acts as an agonist and increases the 
peptide agonist-induced signalling of MC4 receptors (Holst et al. 2002), but in 
another case, these ions exhibited no agonistic properties and reduced the 
peptide agonist-induced signalling in Gs protein pathway (Lagerström et al. 
2003). 
Ligand binding is also modulated by the oligomerization of MC4 receptors 
(Kopanchuk et al. 2006; Lensing et al. 2019). There is growing number of 
studies showing that MC4 receptors can form (homo- and hetero-) dimers or 
higher order oligomers (Kopanchuk et al. 2005; Elsner et al. 2006; Kopanchuk 
et al. 2006; Nickolls and Maki 2006; Rediger et al. 2009; Chapman and Findlay 
2013; Müller et al. 2016). It has been demonstrated that ligand binding and 
signalling of MC4 receptor homodimers is a complex dynamic process, which is 
governed by asymmetric regulation of co-operative binding sites (Kopanchuk et 
al. 2005; Kopanchuk et al. 2006; Lensing et al. 2019). In addition, ligand 
binding to MC4 receptors can also be modulated by several accessory proteins 
(Cooray and Clark 2011; Asai et al. 2013).  
 
 
1.2. Characterization of ligand binding to GPCRs 
Binding to a target GPCR is essential for the pharmacological action of a drug 
molecule. Therefore, drug development has mainly focused on finding selective 
drug candidates with high affinity binding to the target receptors. Although the 
affinity is important, it does not reveal much about the kinetic properties of the 
ligands. There is a growing understanding that ligand’s association rate and 
residence time (receptor occupation period by a ligand) can also be important 
indicators for discovering drug candidates with increased signalling efficacy, 
duration, and selectivity (Copeland et al. 2006; Hoffmann et al. 2015; Meyer-
Almes 2016; Sykes et al. 2019). Therefore, ligand binding assays that enable to 
study the affinity, as well as the kinetic aspects of ligand-receptor interactions, 
are becoming increasingly appreciated.  
 
 
1.2.1. Ligand binding assays 
Majority of methods that are used to study GPCR and ligand interactions imple-
ment some type of labelling. After the introduction of radioisotope labelled 
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ligands at the end of 1960s (Paton and Rang 1965; Lefkowitz et al. 1970), the 
radioligand binding assay became widely used for the determination of affinity 
and kinetic properties of ligand binding to the receptors. Although the highly 
sensitive radioactive method is still often used today, it poses limitations for 
kinetic studies, due to the need to separate receptor-bound ligands from free 
ligands, which is usually achieved by filtration. Instead, a bead-based scintilla-
tion proximity method could be used for kinetic measurements of radioligand 
binding to receptors  (Xia et al. 2016). Whereas the critical early time points 
could still be lost due to the settling of beads. In addition, the use of radioactive 
ligands poses restrictions due to the safety level, waste disposal, and high cost 
issues.  
The availability of fluorophores with high brightness and photostability has 
enabled the development of fluorescence-based methods to measure ligand 
binding to GPCRs (Hertzberg and Pope 2000). Binding of labelled ligands to 
receptors may alter the properties of the fluorophores, such as fluorescence 
spectrum, intensity, lifetime, rotational and/or translational mobility. Most of 
the fluorescent methods are suitable for continuous online monitoring of 
receptor-ligand interactions, as there is no need for the separation of unbound 
ligands. High-sensitivity fluorescence measurements can be carried out in a 
population of molecules or in a single molecule level (Hern et al. 2010; Kasai et 
al. 2011). Ligand binding properties of GPCRs have been studied using fluore-
scence intensity (FI), fluorescence anisotropy (FA), fluorescence correlation 
spectroscopy (FCS) and (Förster/bioluminescence) resonance energy transfer 
(FRET/BRET) methods (Hoffmann et al. 2015; Sykes et al. 2019). Although 
these techniques have several advantages, they are also prone to some limita-
tions, connected with autofluorescence, quenching and scattering of fluore-
scence emission, and inner-filter effects. Fluorescent methods are becoming 
increasingly popular, as high affinity fluorescent tracers are already available 
for numerous receptors (Ciruela et al. 2014; Vernall et al. 2014). Although, the 
fluorescent labelling can lead to substantial changes in the biochemical pro-
perties of ligands (especially for small-molecule ligands), which should, 
therefore, be treated as novel chemical entities (Vernall et al. 2014). However, 
the use of fluorophores is safer, and their waste disposal is cheaper compared to 
radioactive ligands.  
 
 
1.2.1.1. Fluorescence anisotropy assay 
Fluorescence anisotropy (FA) method is used to study various molecular inter-
actions, including ligand binding to the receptor. FA method detects the change 
in rotational freedom of the fluorescent ligand upon the receptor binding pro-
cess. This technique is based on the principle that receptor-bound fluorescent 
ligands that are excited by linearly polarized light emit polarized light, and 
fluorescent ligands that are freely rotating in solution emit depolarized light  
(Weber 1952; Owicki 2000). The values of fluorescence anisotropy (FA) are 
15 
obtained experimentally from the measurement results of fluorescence inten-
sities parallel and perpendicular to the plane of excitation light, as shown in the 
following equation:  
 
    𝐹𝐴 = ୍౅౅ି఼୍୍౅౅ାଶ×఼୍  ,                                                    (1) 
 
where I୍୍ and Iୄ denote the fluorescence intensities parallel and perpendicular to 
the plane of excitation light and their sum (I୍୍ + 2 × Iୄ) corresponds to the total 
fluorescence intensity (TFI) of emitted light (Jablonski 1960). Instrumental 
differences in the sensitivities of parallel and perpendicular polarizers are 
calibrated by G-factor correction (Owicki 2000).  
The FA ligand binding assay is easy-to-perform due to a simple principle 
and a low-demand apparatus that allows continuous online measurement of 
several samples simultaneously. Due to the high sensitivity, it is possible to 
perform experiments on small volumes of microtiter plates, which ensures 
economic high-throughput screening. Promising results have been obtained 
using this assay in kinetic studies of several GPCRs, such as endothelin A, 
muscarinic M1, A2A adenosine, melanocortin-4, serotonin 1A and dopamine 1 
receptors (Junge et al. 2010; Huwiler et al. 2010; Kecskés et al. 2010; Veiksina 
et al. 2010; Tõntson et al. 2014; Allikalt et al. 2018). The high quality of FA 
data enables to determine the binding affinities and kinetic parameters of 
labelled and unlabelled ligands and mechanism of the binding process (Rinken 
et al. 2018). Although, the data analysis is more complex compared to radio-
ligand binding assays, as the depletion of the fluorescent ligand in the binding 
process has to be taken into account in FA experiments (Roehrl et al. 2004; 
Veiksina et al. 2010). This is caused by the ratiometric nature of this method, 
which requires that the fluorescent ligand and the receptor to be used in 
comparable concentrations. 
There is a variety of receptor sources that have been implemented for ligand 
binding assays starting from live organisms to solubilized receptors in liposome 
or high-density lipoprotein systems (Früh et al. 2011; Mitra et al. 2013). The 
use of native receptor sources for high-throughput assays is limited due to the 
low concentration GPCRs. Therefore, systems that enable overexpression of 
recombinant receptors are often used for these assays. Proper protein proces-
sing, including protein folding and post-translational modifications (glycosyla-
tion, phosphorylation, fatty acid acetylation) is necessary for recombinant 
GPCRs to retain properties close to its native receptors. Mammalian cells are 
most suitable for the processing of recombinant mammalian GPCRs, but the 
receptor expression levels remain relatively low. Whereas, insect cells enable 
mammalian-like protein processing but exhibit higher protein expression. 
Although, insect cells pose limitations for glycosylation (Katoh and Tiemeyer 
2013), this can be solved by using an insect cell line that has been developed to 
allow higher eukaryotic like glycosylation (Aumiller et al. 2012). 
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The expression of recombinant GPCRs is achieved by the introduction of 
foreign genes into cells using chemical, physical or biological techniques. A 
widely used biological technique uses baculoviruses as foreign gene expression 
vectors for the production of large amounts of recombinant GPCRs. Recombi-
nant baculoviruses are most commonly used in combination with the insect cell 
lines Sf9 or Sf21 (cells isolated from pupal ovarian tissue of fall armyworm, 
Spodoptera frugiperda). The baculovirus vector initiates early gene expression 
in the cell, leaving more time for post-translational modifications to occur 
(Massotte 2003). The combined insect cell-baculovirus expression system is a 
very efficient system for the large-scale production of recombinant receptors 
with the native protein-like properties. 
It has been shown that a good signal output for FA ligand binding assay can 
be achieved with the implementation of membrane preparations of recombinant 
Sf9 cells (Veiksina et al. 2010). Although, the membrane preparations pose 
limitations due to the uncontrolled size of lipoparticles and orientation of the 
receptors. A novel approach to improve the experimental conditions for FA is 
the implementation of budded baculoviruses (BBVs), which display recombi-
nant receptors on their surface (Veiksina et al. 2014). BBVs are surrounded by 
the plasma membrane that is derived from the infected Sf9 cells when the 
nucleocapsids bud out of the host cells (Braunagel and Summers 1994). In the 
BBVs (250–300 nm in length, 30–60 nm in diameter), membrane proteins are 
captured in the correct orientations forming a homogenous system for the FA 
ligand binding assays. Implementation of baculoviruses is a two in one method 
for gene delivery and receptor expression, which requires only Biosafety Level 
1 conditions. 
 
1.2.2. Functional assays 
Functional assays are used to determine the biological activity and efficacies of 
ligands upon binding to the receptors. Many GPCRs mediate the biological 
effects of ligands through a cyclic adenosine monophosphate (cAMP) signalling 
pathway. Therefore, many functional assays are directed to detect changes in 
cAMP level in cells upon receptor activation. Commonly used methods imple-
ment labelled cAMP in competition assays or labelled cAMP-binding partners 
(PKA, Epac, cyclic nucleotide gated ion channels) in non-competition assays to 
determine the changes in the endogenous cAMP levels using radioactive or non-
radioactive signals (Hill et al. 2010; Zhang and Xie 2012).  
The FRET-based biosensors offer novel possibilities to monitor the activa-
tion of cAMP production in real-time in living cells. The biosensor consists of a 
cAMP recognition domain that is sandwiched between donor and acceptor 
fluorophores with overlapping emission and excitation spectra. The FRET-
based technique is based on the principle that a radiationless energy transfer 
takes place if donor and acceptor fluorophores are close (d ˂ 10 nm) (Klaren-
beek et al. 2011). Whereas, the efficiency of FRET depends on the distance and 
orientation between the two fluorophores, which is altered upon cAMP binding 
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to the biosensor’s recognition domain (Lohse et al. 2007; Okumoto et al. 2012). 
Therefore, the change in FRET signal depends on the change in cAMP con-
centration in the cell. In most cases, the values of FRET are obtained experi-
mentally from the fluorescence intensity ratio of acceptor and donor fluoro-
phores (or vice versa). Whereas, the issues of background fluorescence and 
spectral bleed-through can be compensated if the relative change of FRET 
(∆FRET) is calculated as shown in the following equation:   
 
∆FRET = ൫𝐼଴
௔௖௖௘௣௧௢௥ 𝐼଴ௗ௢௡௢௥ൗ ൯ − (𝐼௧௔௖௖௘௣௧௢௥ 𝐼௧ௗ௢௡௢௥ൗ )
(𝐼଴௔௖௖௘௣௧௢௥ 𝐼଴ௗ௢௡௢௥ൗ )
,                    (2) 
 
where I0acceptor, I0donor and Itacceptor, Itdonor correspond to the fluorescence emission 
intensities of the acceptor and donor fluorophores before and after cell treat-
ment, respectively.  
First generation FRET-biosensors were designed based on cAMP-sensitive 
protein kinases or ion channels as the recognition domains (Adams et al. 1991; 
Fagan et al. 2001; Rich et al. 2001). These biosensors were soon substituted 
with cAMP sensitive Epac-based recognition elements, because of their uniform 
cellular expression, increased sensitivity, and higher signal-to-noise ratio. There 
are four generations of biosensors based on either Epac1 or Epac2 proteins that 
are tagged with various FRET-pairs (Nikolaev et al. 2004; Ponsioen et al. 2004; 
van der Krogt et al. 2008; Goedhart et al. 2010; Klarenbeek et al. 2015). Impor-
tantly, if native cAMP recognition elements are used for biosensors, they should 
be modified to become catalytically inactive to avoid disruption of cellular 
functions (Okumoto et al. 2012). The fourth-generation Epac-based FRET 
sensors have demonstrated higher dynamic range, brightness, and photostability 
(Klarenbeek et al. 2015). This was achieved by implementing modified struc-
ture of Epac1 and novel fluorophores. In the case of Epac-FRET sensors, the 
binding of cAMP induces a conformational change, which makes the conditions 
for FRET unfavourable. Therefore, FRET signal is high when there is low level 
of cAMP and low when there is high level of cAMP in the cell.  
FRET-based biosensors were first microinjected into cells (Adams et al. 
1991), but the development of genetically encoded sensors allowed non-inva-
sive expression of biosensors, and monitoring of FRET change in living cells 
(Zaccolo and Pozzan 2002). Mammalian cells are most suitable to characterize 
the signal transduction of human GPCRs coupled to the cAMP pathway. Imple-
mentation of recombinant baculoviruses as foreign gene expression vectors in 
mammalian cells allow efficient transgene expression levels with low toxicity 
(Kost and Condreay 2002; Mazina et al. 2012; Mazina et al. 2013; Mazina et al. 
2015a; Mazina et al. 2015b). This BacMam system is safe and convenient to 
use, as baculoviruses cannot replicate in mammalian cells and require only 
Biosafety Level 1 conditions.  
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2. AIMS OF THE STUDY 
The general aim of the study was to gain additional information about ligand 
binding, allosteric modulation, and constitutive activity of melanocortin-4 
(MC4) receptors. To achieve this goal, several particular tasks were raised 
within this study: 
• Optimization of the preparation method of budded baculoviruses and 
development of a fluorescence anisotropy (FA)-based assay for the 
characterization of ligand binding kinetics to MC4 receptors. 
• Design and implementation of novel fluorescent ligands with different 
kinetic properties for ligand binding studies of MC4 receptors. 
• Implementation of a cAMP biosensor assay for the characterization of 
signal transduction of MC4 receptors in live cells. 
• Characterization of the influence of different metal ions on the ligand 
binding to MC4 receptors and on the activation of the receptor-dependent 
cAMP accumulation. 
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3. MATERIALS AND METHODS 
3.1. Cell lines and Reagents 
Spodoptera Frugiperda (Sf9) cells (Invitrogen Life Technologies) were grown 
as a suspension culture in antibiotic- and serum-free growth medium EX-
CELL® 420 (Sigma-Aldrich) at 27 ºC in a non-humidified incubator. Chinese 
hamster ovary (CHO-K1) cells (ATCC®, LGC Standards) were modified to 
stably express human wild type MC4 receptors (Link et al. 2020). The 
pcDNA3.1+ expression vectors (Invitrogen) encoding MC4 receptors (Missouri 
S&T cDNA Resource Center) were transfected into CHO-K1 cells using ExGen 
500 (Fermentas) according to the manufacturer’s description and selected using 
500 μg/ml geneticin (PAA Laboratories). Both, naive and modified CHO-K1 
cells were grown as an adherent monolayer culture in high glycose Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Sigma-Aldrich) supplemented with 10% 
fetal bovine serum (Sigma-Aldrich), 100 U/ml penicillin, 0.1 mg/ml strepto-
mycin (PAA Laboratories) and in the latter case also with 400 μg/ml geneticin 
at 27 ºC in a humidified incubator with 5% CO2. 
Na-HEPES (Amresco), NaCl (AppliChem), KCl (AppliChem), Pluronic F-
127 (Sigma-Aldrich), and Complete EDTA-Free Protease Inhibitor Cocktail 
(Roche Applied Science) were used to prepare the incubation buffer (IB). CaCl2 
(AppliChem), MgCl2 (AppliChem), MnCl2 (AppliChem), ZnSO4 (ReaChim), 
CuCl2 (Sigma-Aldrich), BaCl2 (ReaChim) or Sr(NO3)2 (Acros Organics) were 
used to prepare salt stock solutions. Metal ion effects were studied using ethylen-
diaminetetraacetic acid (EDTA, Merck). Unlabelled ligands of MC4 receptors 
were purchased from Tocris Bioscience (NDP-α-MSH, SHU9119, THIQ, HS024) 
and Bachem (JKC-363). Custom synthesis of MC4 receptor fluorescent ligands 
was ordered from AnaSpec (Cy3B-NDP-α-MSH, Ac-Ser-Tyr-Ser-Nle-Glu-His-
DPhe-Arg-Trp-Gly-Lys(Cy3B)-Pro-Val-NH2; TAMRA-NDP-α-MSH, TAMRA-  
Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-Lys-Pro-Val-NH2) and CEPEP 
EESTI (UTBC101, Cy3B-Nle-c[Asp-His-DNal(2’)-Arg-Trp-Lys]-NH2; 
UTBC102, Ac-Lys(Cy3B)-c[Asp-His-DNal(2’)-Arg-Trp-Lys]-NH2). Forskolin 
(Tocris Bioscience) was used for a direct activation of adenylyl cyclase. The 
ligands were stored at ‒20 °C or lower in dimethyl sulfoxide (DMSO, 
AppliChem). Sodium butyrate used for the induction of gene expression was 
from Sigma-Aldrich. Expression vectors were purchased from Invitrogen  
Life Technologies (pcDNA3.1(+), pFastBac™1) or kindly provided by  
Dr. Kees Jalink from The Netherlands Cancer Institute (pcDNA3.1(+)-
mTurq2∆_Epac(CD,∆DEP, Q270E)_tdcp173Ven, referred to as EpacH187). 
Restriction enzymes (FastDigest RruI, FastDigest EcoRI, EcoRI, Eco105I) were 
from Thermo Fisher Scientific. 
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3.2. Recombinant expression systems in GPCR assays 
3.2.1. Budded baculovirus preparation 
Recombinant baculoviruses of human MC4 receptors were generated via the 
transfection of Sf9 cells, as described by Veiksina et al. (Veiksina et al. 2010). 
The initial virus was amplified to achieve a high titer (108 ivp/ml), which was 
determined by a cell size-based assay (Veiksina et al. 2015; Laasfeld et al. 
2017). The high-titer virus was then used for the production of budded baculo-
viruses by infecting Sf9 cells at a density of 2 × 106 cells/ml at the multiplicity 
of infection (MOI) of 3-30. The infection was carried out for 48-120 h at 27 °C. 
The cells were separated from budded baculoviruses by centrifugation at 1,000 
for 10 min. The supernatant containing the virus was then concentrated 10–50 
times, either by tangential flow filtration (TFF) or by high-speed centrifugation 
(Veiksina et al. 2015). For the TFF concentration, the supernatant was dia-
filtrated at 4 °C using polyethersulfone membranes with a cutoff of 100 kDa or 
300 kDa (LV CentramateTM Lab TFF system with OmegaTM Membrane LV 
CentramateTM Cassettes, Pall®). The insect cell growth medium was exchanged 
for the incubation buffer (IB), which was then reduced to the desired volume. 
For the centrifugal concentration, the supernatant was centrifuged at 48,000g for 
40 min at 4 °C and the obtained pellet was washed and suspended in the desired 
IB volume. The IB (pH 7.4) contained 11 mM Na-HEPES, 135 mM NaCl,  
5 mM KCl, 0.1% Pluronic F-127 (excl. for TFF), and Complete EDTA-Free 
Protease Inhibitor Cocktail (according to the manufacturer’s description). The 
IB was also supplemented with 2 mM CaCl2 and 1 mM MgCl2 unless the 
budded baculoviruses was further used in the studies of divalent metal ion 
effects (Link et al. 2020). The budded baculovirus (BBV) preparations were 
aliquoted and stored at ‒90 °C or lower.  
 
 
3.2.2. BacMam-EpacH187 virus 
BacMam viruses of FRET-based cAMP biosensors were generated via trans-
fection of Sf9 cells as previously described by Mazina et al. (Mazina et al. 
2015a; Mazina et al. 2015b). In brief, the cAMP biosensor construct EpacH187 
(Klarenbeek et al. 2015) was cloned into the pFastBac™1 vector using  
FastDigest RruI and FastDigest EcoRI restriction enzymes for EpacH187 and 
EcoRI and Eco105I for pFastBac™1. The resulting pFastBac-EpacH187 construct 
under the control of the cytomegalovirus promoter was transformed into 
DH10BacTM competent cells (Invitrogen Life Technologies) to generate recom-
binant bacmids. The purified and verified bacmids were transfected into Sf9 
cells with a transfection reagent ExGen 500 to generate BacMam viruses based 
on the Bac-to-Bac® expression system manual (Invitrogen Life Technologies). 
The initial virus was amplified to achieve a high titer, which was determined by 
a cell size-based assay (Laasfeld et al. 2017). The amplified BacMam virus was 
aliquoted and stored at ‒90 °C. 
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3.3. Fluorescence anisotropy assay 
Fluorescence anisotropy (FA) measurements were performed with Cy3B-NDP-
α-MSH and TAMRA-NDP-α-MSH (Veiksina et al. 2010) and with novel 
fluorescent ligands UTBC101 and UTBC102 (Fig. 1). The concentration of 
novel fluorescent ligands was determined by the absorbance of Cy3B (ε558 = 
130,000 M-1 cm-1). Budded baculoviruses of MC4 receptors were used as a 
homogenous receptor source, as described by Veiksina et al. (Veiksina et al. 
2014; Veiksina et al. 2015). In brief, assays were carried out in the incubation 
buffer in a total volume of 100 μl at 27 °C using 96-well half area, flat-bottom 
polystyrene NBS microtiter plates (Corning). Fluorescence intensities were 
measured on a PHERAstar (BMG Labtech, Germany) or Synergy™ NEO 
(BioTek, USA) microplate reader using optical modules with excitation and 
emission filters of 540 (slit 20 nm) and 590 (slit 20 nm) or 530 (slit 25 nm) and 
590 (slit 35 nm), respectively. Parallel-polarized light was used to excite the 
samples, and the dual detection mode was used to register the emission. This 
allows to simultaneously record intensities that are parallel (I||) and perpendi-
cular (I⊥) to the plane of excitation light. Erythrosine B was used as a standard 
to correct the sensitivities of both emission channels (G-factor) (Thompson et 
al. 2002). The fluorescence intensities (I||, I⊥) were also background corrected 
(Owicki 2000). All measurements were carried out in kinetic mode after the 
addition of budded baculoviruses to the fluorescent ligand with or without a 
competing ligand corresponding to the nonspecific and total binding, respecti-
vely.  
In saturation binding assays, serial dilutions of budded baculoviruses were 
added to two fixed concentrations of the fluorescent ligands (Cy3B-NDP-α-
MSH, UTBC101, or UTBC102). Nonspecific binding was determined in the 
presence and total binding in the absence of 3 μM SHU9119 or NDP-α-MSH. 
Reactions were carried out in the IB with 2 mM CaCl2 and 1 mM MgCl2 
(Veiksina et al. 2015; Link et al. 2017) and with 1 mM EDTA for the removal 
of heavy metal ions from the BBV preparation (Link et al. 2020). The associa-
tion kinetics of Cy3B-NDP-α-MSH and UTBC101 was measured for 3 h and 
UTBC102 for 0.5 h. After that, the dissociation was initiated with 3 μM 
SHU9119 or NDP-α-MSH. 
In competition binding assays, fixed concentrations of MC4 receptors and 
fluorescent ligand (UTBC101 or UTBC102) were incubated with serial dilu-
tions of various unlabelled ligands (NDP-α-MSH, THIQ, SHU9119 or JKC-
363). Reactions were carried out in the IB with 2 mM CaCl2 and 1 mM MgCl2 
(Link et al. 2017). The budded baculoviruses were pre-incubated for 0.5 h with 
either the unlabelled (pre) or the fluorescent ligand (post). After that, the 
competition reaction was initiated with either the fluorescent (pre) or the un-
labelled ligand (post), and it was measured for 370 min. The time points of the 
competition assays were calculated from the addition of the fluorescent ligand 
to the medium containing MC4 receptors.  
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In divalent metal ion modulated binding assays, a fixed concentration of 
MC4 receptors were added to a fixed concentration of the fluorescent ligand 
(UTBC101, UTBC102 or TAMRA-NDP-α-MSH) in the presence (nonspecific 
binding) or absence (total binding) of 3 μM SHU9119. Reactions were carried 
out in the IB with 1 mM CaCl2 in the presence or absence of EDTA (0.01-1 
mM). Divalent metal ion salt solutions (MgCl2, CaCl2, Sr(NO3)2, BaCl2, MnCl2, 
ZnSO4 or CuCl2) were added to the binding reaction from the start or after the 
equilibrium had been achieved (after 3 h for UTBC101, 0.5 h for UTBC102 or 
1.5 for TAMRA-NDP-α-MSH). 
 
 
3.4. BacMam-EpacH187-based FRET assay 
BacMam-EpacH187-based FRET assay was used to measure cAMP accumulation 
in CHO-K1 and CHO-K1-MC4R cells, as described previously by Mazina et al. 
(Mazina et al. 2015a; Mazina et al. 2015b). The high-titer BacMam virus was 
used to transduce mammalian cells at the density of 105 cells/well at MOI of 9-
25. The cells were seeded on a black clear-bottom 96-well cell culture plate 
(Corning Life Sciences) in growth medium containing the BacMam virus and 
12 mM sodium butyrate in a 100 μl volume. The transduced cells were 
incubated for 30 h at 30 °C for the expression of cAMP biosensor. Before the 
experiment (0.5 h), the cell growth medium was replaced with the IB (excl. 
protease inhibitors) with 1 mM CaCl2. The assays were performed on a 
Synergy™ NEO microplate reader (BioTek), with excitation at 420/50 nm and 
simultaneous dual emission at 485/20 nm and 540/25 nm. The fluorescence 
intensities of the FRET-based biosensors in the cells were measured before and 
after the addition of a ligand and/or a modulator. The change in FRET values 
was calculated, as shown in Equation 2.  
 
 
3.5. Data analysis 
Aparecium 2.0.20 software (http://gpcr.ut.ee/aparecium.html), which is deve-
loped in our laboratory, was used for the management of experimental data. The 
data was analysed using MATLAB 7.1 (MathWorks, Inc., Natick, MA, USA) or 
GraphPad Prism 5.04 (GraphPad Software, USA) with built-in or user-defined 
optimization (Veiksina et al. 2014) binding models. The data are presented as 
the mean ± standard deviation of at least three independent experiments unless 
stated otherwise. Statistically significant differences were determined by 
Student’s t-test or nonparametric Mann-Whitney U test, where the significance 
level was set to 0.05.  
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4. RESULTS AND DISCUSSION 
4.1. Development of fluorescence anisotropy assay 
implementing budded baculoviruses  
Ligand binding to GPCRs, including to MC4 receptors, is a complex dynamic 
process, which requires a measurement system that would allow real-time 
monitoring of the reaction to get a better insight (Kopanchuk et al. 2005; 
Kopanchuk et al. 2006; Hoffmann et al. 2015). Fluorescence anisotropy (FA) 
method used together with bright and photostable fluorescent ligands can be a 
powerful tool to conduct kinetic measurements of ligand binding. In the current 
work, the fluorescent ligand Cy3B-NDP-α-MSH was used to develop a specific 
step-by-step protocol for FA-based method to study the kinetics of ligand 
binding processes of MC4 receptors and GPCRs in general (Veiksina et al. 
2015).  
An important aspect of the FA-based assay development is the source of 
receptors. Due to the ratiometric nature of FA, similar concentrations of recep-
tors and ligands are required, which can be achieved by using receptor sources 
that express high levels of GPCRs. Good results for FA assay have been 
achieved with the implementation of Sf9 membrane preparations, which exhibit 
high expression levels of recombinant receptors (Veiksina et al. 2010). How-
ever, the preparation of budded baculoviruses (BBV) that display receptors of 
interest on their membranes is a uniform system that further improves the 
quality of FA assay results (Veiksina et al. 2014). As the implementation of 
BBVs in FA-based GPCR studies is a novel approach (Fig. 1), conditions for its 
production needed to be optimized.  
The infection conditions of Sf9 cells with recombinant baculoviruses and the 
collection methods of budded baculovirus are important factors to achieve high 
expression levels of GPCRs. In case of MC4 receptors, the multiplicity of infec-
tion (MOI) of Sf9 cells was varied from 3 to 30 using high-titer baculoviruses 
and the virus collection time was varied from 48 h to 120 h after the infection. 
After the infection period, Sf9 cells were separated from budded baculoviruses 
by low-speed centrifugation (1,000g). Subsequently, the obtained supernatant 
fraction, containing budded baculoviruses, was concentrated by using two 
methods – high-speed centrifugation and tangential flow filtration (TFF). In 
addition, sucrose gradient centrifugation (>80,000g) and ultrafiltration using 
protein concentrating cartridges were also studied for the preparation of virus-
like particles. However, these methods were disregarded, as sucrose gradient 
centrifugation did not improve results, and ultrafiltration revealed considerably 
lower yields (Oliver Pulges unpublished data).  
In the case of high-speed centrifugation, the supernatant containing BBVs 
was centrifuged at 48,000g for 40 min to collect the viruses as a pellet. The 
pellet was suspended in the IB to obtain the BBV preparation with the desired 
concentration. In the case of TFF concentration, the supernatant containing 
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BBVs was pumped in a tangential direction to the membrane, which helped to 
avoid build up and clogging of the membrane pores. The insect cell growth 
medium was passed through the membrane by applying pressure, whereas the 
budded baculovirus particles were largely retained in the system for repro-
cessing. Two different polyethersulfone membranes with a cutoff of 100 kDa 
and 300 kDa were tested, from which the latter proved to be more suitable for 
the BBVs. During the reprocessing with the TFF system, the BBV retentate was 
washed with the IB (without Pluronic F-127 to prevent foaming), after which 
the amount of the IB was reduced to the desired volume and was collected as 
the BBV preparation. A suitable amount of BBVs containing MC4 receptors for 
FA assay was achieved by concentrating the supernatant in the range of 10–50 
times, considering the initial volume of the Sf9 cell suspension. 
The quality of BBV preparations containing MC4 receptors was evaluated in 
FA-based ligand binding assay (Fig. 1). Optimal expression of the receptors 
was achieved at MOI of 3 and with the infection period of 96 h (Veiksina et al. 
2015). The estimated concentration of MC4 receptor binding sites was about 5 
times lower in the BBV preparation obtained by TFF compared to centrifu-
gation. The lower yield of TFF concentration compared to centrifugation may 
have been caused due to the loss of some BBVs in contact with the membrane. 
As the whole medium was not replaced, some proteases may have remained in 
the preparation. In principle, it was shown that TFF is applicable for the 
production of BBVs, but it is less effective than centrifugation in small-scale 
production, where the modest loss of receptors is more critical. In large-scale 
production, the use of TFF would be more reasonable as it is potentially less 
labour-intensive and less harmful to BBVs than centrifugation. Since studies 
within the current thesis did not require large-scale receptor production, it was 
decided hereafter to use the centrifugation method for the preparation of BBVs. 
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Figure 1. Fluorescence anisotropy (FA) based ligand binding assay with the imple-
mentation of budded baculoviruses as a receptor source. In the FA-based assay 
system, bright and photostable fluorescent ligands were used to characterize the ligand 
binding properties to GPCRs. Three custom synthesized peptides coupled with Cy3B-
tag were used for MC4 receptor studies – Cy3B-NDP-α-MSH, UTBC101, and 
UTBC102. Cy3B-NDP-α-MSH is the derivative of a high affinity agonist NDP-α-MSH; 
UTBC101 and UTBC102 are the derivatives of high affinity antagonist SHU9119 of 
MC4 receptors. Budded baculoviruses (BBVs) are used as a melanocortin-4 (MC4) 
receptor source that display the receptors on their surfaces. BBVs were obtained by the 
infection of Sf9 (Spodoptera frugiperda) cells with recombinant baculoviruses that 
encode the expression of MC4 receptors. During the infection cycle, baculoviruses bud 
from the insect cell surface. After budding from the cell, viruses are surrounded by the 
host cell membranes that carry the recombinant receptors expressed by the host cell. 
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FA-based ligand binding assays were carried out on microplate readers for the fluore-
scence measurements. Fluorescent ligand binding to the receptors can be characterized 
by the change in FA values, which were calculated from the experimentally measured 
fluorescence intensities that are parallel (I୍୍) and perpendicular (Iୄ) to the plane of 
excitation light. FA values are low when fluorescent ligands are free in the solution and 
high when fluorescent ligands are bound to the receptor. Global data analysis (Veiksina 
et al. 2014) was used for the fitting of FA data to characterize the binding properties of 
labelled and unlabelled ligands.  
 
4.2. Novel fluorescent ligands for MC4 receptors 
The fluorescent ligand Cy3B-NDP-α-MSH (Fig. 1), which was used to develop 
the FA-based assay system, enables to obtain high quality ligand binding data 
for MC4 receptors. However, the slow dissociation kinetics of this reporter 
ligand limits reaching equilibrium in ligand binding studies. As there were no 
commercially available fluorescent ligands for MC4 receptors, it was decided to 
synthesize two novel fluorescent derivatives of a high affinity antagonist 
SHU9119. Cy3B was coupled directly to SHU9119 at the first amino acid 
residue Nle resulting in a positively charged fluorescent ligand UTBC101 (Fig. 
1). Whereas, UTBC102 was obtained by exchanging the amino acid that was 
coupled to Cy3B from Nle to Lys, which further increased the positive charge 
of the ligand (Fig. 1). The red-emitting Cy3B was chosen as it has proven to be 
a stable and high quantum yield fluorophore (Cooper et al. 2004; Turek-Etienne 
et al. 2004) suitable for FA measurements (Veiksina et al. 2010). The affinities 
of two novel fluorescent ligands were estimated from kinetic binding data as 
well as from a time snapshot of binding data corresponding to near equilibrium 
conditions. 
The addition of BBV preparation containing MC4 receptors to the fluore-
scent ligands caused a time-dependent increase in the FA values (Fig. 2 A and 
B, filled shapes). Whereas in the presence of excess NDP-α-MSH or SHU9119 
the FA change was negligible (Fig. 2 A and B, open shapes). The difference 
between these FA values could be attributed to the specific ligand binding to 
MC4 receptors. After the binding of UTBC101 (3 h) and UTBC102 (0.5 h) 
reached a plateau, the dissociation reaction was initiated by the addition of 
3 μM NDP-α-MSH or SHU9119 (Fig. 2 A and B, filled shapes indicated by an 
arrow). This revealed that UTBC101 had a significantly slower dissociation 
compared to UTBC102 (half-lives of 160 ± 18 min and 7 ± 2 min, respectively). 
Whereas both ligands demonstrated faster dissociation kinetics compared to 
Cy3B-NDP-α-MSH having approximately 1.4 and 30 times shorter half-lives, 
respectively (Veiksina et al. 2014; Link et al. 2017). The apparent dissociation 
rate constants (koff) were estimated by one-phase exponential decay for 
UTBC101 ((1.1 ± 0.3) × 10−1 min−1) and UTBC102 ((4.4 ± 0.5) × 10−3 min−1). 
These values were also used for the global fitting of the observed binding data, 
as described by Veiksina et al. (Veiksina et al. 2014). It was found that the 
apparent association rate constants (kon) were quite similar, having values of 
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(1.8 ± 0.3) × 107 M−1 min−1 for UTBC101 and (3.7 ± 0.8) × 107 M−1 min−1 for 
UTBC102. The apparent dissociation constants (Kd) calculated from ratio of  
the kinetic rate constants (koff/kon) were 0.24 ± 0.04 nM for UTBC101 and  
3.0 ± 0.6 nM for UTBC102. The concentration of MC4 receptor binding sites in 
the BBV preparation was estimated to be twice as high for UTBC101 (48 ± 4 nM) 
compared to UTBC102 (21 ± 4 nM). 
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Figure 2. Kinetics of the fluorescent ligand binding to MC4 receptors in budded 
baculoviruses. The binding reaction was initiated by addition of MC4 receptors to 
UTBC101 (0.4 nM and 4 nM) (A) or UTBC102 (0.5 nM and 7 nM) (B) in the absence 
(filled shapes) or presence (open shapes) of 3 µM SHU9119. The concentration of MC4 
receptor binding sites for the fluorescent ligands was estimated to be 2.5 nM. After 3 h 
(A) or 0.5 h (B), the dissociation was initiated by the addition of 3 µM SHU9119 
(shown with an arrow). The fluorescence intensities were measured, and corresponding 
changes in FA values were calculated. Data are from a representative experiment of at 
least three independent experiments performed in duplicates. 
 
 
The addition of an increasing amount of BBVs containing MC4 receptors to the 
fluorescent ligands caused an increase in the FA values corresponding to the 
total binding (Fig. 3 A and B, filled shapes). There was also an increase in the 
non-specific binding (Fig. 3 A and B, open shapes), but it was significantly 
lower than the total binding. These binding curves of the fluorescent ligands to 
MC4 receptors correspond to the binding data obtained at near equilibrium 
conditions (Fig. 3). Near equilibrium conditions were achieved for UTBC101 
after 3 h binding and for UTBC102 after 0.5 h binding to MC4 receptors (Link 
et al. 2017). The binding parameters were obtained by simultaneous fitting of 
the total and non-specific signal, which takes into account the depletion of the 
fluorescent ligand during the reaction (Veiksina et al. 2014). The obtained Kd 
values were 0.21 ± 0.03 nM for UTBC101 and 3.7 ± 1.1 nM for UTBC102, 
which are in agreement with the Kd values that were calculated from the ratio  
of the apparent kinetic rate constants. The estimated concentration of MC4  
receptor binding sites in the BBV preparation were 40 ± 4 nM for UTBC101 
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and 18 ± 4 nM for UTBC102, which are in good agreement with the values 
obtained from the kinetic binding curves.  
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Figure 3. Time snapshots of the binding curves of the fluorescent ligands to MC4 
receptors in budded baculoviruses. Fixed concentrations of UTBC101 (0.4 nM and  
4 nM) (A) or UTBC102 (0.5 nM and 7 nM) (B) were incubated with different amounts 
of MC4 receptors in the absence (filled shapes) or presence (open shapes) of 3 µM 
SHU9119. The fluorescence intensities were measured after a 3 h (A) and 0.5 h (B) 
incubation period. Corresponding changes in FA values were calculated, and the global 
fitting of this data was used to characterize the binding properties and MC4 receptor 
binding site concentrations (depicted on the lower x-axis) for these ligands. Data are 
from a representative experiment of at least three independent experiments performed in 
duplicates. 
 
 
Although SHU9119 is mainly known as an MC4 receptor antagonist (Hruby et 
al. 1995) the biological activity of its novel derivatives needed to be deter-
mined. The biological activity of the novel fluorescent ligands was studied in 
CHO-K1 cells stably expressing MC4 receptors. To estimate the activation of 
MC4 receptors coupled to Gs proteins, the accumulation of cAMP was detected 
by a FRET-based biosensor, which is expressed in the cells using the BacMam 
system (Mazina et al. 2015a; Mazina et al. 2015b). MC4 receptor full agonist 
NDP-α-MSH caused a concentration-dependent increase in the ∆FRET values 
corresponding to cAMP accumulation (Fig. 4). The maximal level of cAMP 
accumulation was achieved within 30 minutes. Similar concentration dependent 
increase in cAMP accumulation was also observed for fluorescently labelled 
NDP-α-MSH (Fig. 4). Neither of the novel fluorescent ligands exhibited full 
agonistic properties – UTBC102 behaved as a classical partial agonist (68 ± 
5%), and UTBC101 showed low partial agonistic activity (22 ± 2%) compared 
to NDP-α-MSH (Fig. 4). In our system, low partial agonistic activity was also 
found for HS024 (Fig. 4; 19 ± 3%), the previously known antagonist for MC4 
receptors (Kask et al. 1998). 
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Figure 4. Ligand-dependent activation of cAMP production in CHO-K1 cells with 
MC4 receptors. The ΔFRET values were measured 30 min after the addition of the 
indicated concentrations of ligands to CHO-K1-MC4R cells expressing the cAMP 
biosensor BacMam-EpacH187. After that, fluorescence intensities were measured, and 
corresponding changes in ∆FRET values were calculated and normalized to the 
maximal NDP-α-MSH signal. Data are from a representative experiment of at least 
three independent experiments performed in triplicates. A three-parameter logistic 
function was used to fit the data to characterize the ligand-specific effects shown in the 
table as the mean ± SD. 
 
 
4.3. Fluorescent ligands as tracers to  
characterize unlabelled ligands 
Fluorescent ligands can be used as tracers to determine the affinity and kinetic 
properties of unlabelled ligands binding to GPCRs using competition binding 
assays. Generally, it is assumed that competition binding assays are measured 
when equilibrium has been reached, but this is not always the case as equilib-
rium depends on the kinetic properties of fluorescent tracers as well as on the 
unlabelled competitors (Kopanchuk et al. 2006; Veiksina et al. 2010; Guo et al. 
2013; Rinken et al. 2018). This has to be taken into account in the planning of 
the experiment and in the interpretation of results to avoid over- or unde-
restimation of the unlabelled ligands’ affinity. 
It was found that the apparent pIC50 values also depend on the experimental 
design of the competition experiment (Fig. 5). The pIC50 values of unlabelled 
ligands could be underestimated when MC4 receptors are pre-incubated with the 
fluorescent tracer (Fig. 5, red line) or overestimated when they are pre-in-
cubated with the unlabelled ligand (Fig. 5, blue line) prior to the initiation of the 
competition reaction. In these assays, equilibrium was reached in less than an 
hour using UTBC102 (Fig. 5, solid line) or in more than 3 hours using 
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UTBC101 (Fig. 5, dashed line). Whereas in previous studies using the fluore-
scent tracer Cy3B-NDP-α-MSH, equilibrium was practically not reached in the 
competition binding assays (Veiksina et al. 2014). The time of equilibrium in 
these assays also depended on the unlabelled ligand. The rank order of which of 
the studied unlabelled ligand binds to MC4 receptors the fastest and which one 
the slowest was estimated based on the time of equilibrium (THIQ > JKC-363 > 
SHU9119 > NDP-α-MSH) (Link et al. 2017). The kinetic rate constants of 
unlabelled ligands can be estimated by using multivariable global analysis of 
the competition binding data as described by Rinken et al. (Rinken et al. 2018), 
but this requires precise optimization of experimental conditions and collecting 
a substantial amount of high-quality experimental data. The apparent potencies 
of unlabelled ligands, which were determined with both novel tracers, were in 
good agreement with each other, except for some discrepancies between the 
apparent pIC50 values of SHU9119 (Link et al. 2017). It has been shown that 
unlabelled ligand’s affinity can be underestimated in FA-based competition 
binding assays, if the unlabelled ligand has a substantially higher affinity than 
the fluorescent tracer does (Cha 1975; Huang 2003; Sinijarv et al. 2017; Rinken 
et al. 2018). This is likely the case for SHU9119 and UTBC102 (Fig. 5, solid 
line). 
 
 
Figure 5. Time dependence of the apparent pIC50 values of unlabelled ligands in 
competition with fluorescent ligands binding to MC4 receptors. MC4 receptors in 
budded baculoviruses were preincubated for 0.5 h either with an unlabelled SHU9119 
(blue) or with a fluorescent ligand (red) prior to the initiation of the competition 
reaction. The apparent pIC50 values of unlabelled SHU9119 at different time points 
were calculated from representative competition curves of UTBC101 (dashed line) and 
UTBC102 (solid line) of at least two independent experiments performed in duplicates. 
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4.4. Modulation of the ligand binding to  
MC4 receptors by metal ions 
Ca2+ is an essential cofactor for the high affinity ligand binding to MC4 recep-
tors, which has previously been shown with ligand binding experiments (Ko-
panchuk et al. 2005; Veiksina et al. 2010) and recently confirmed by solving 
the crystal structure of the receptor (Yu et al. 2020). At least 1 mM Ca2+ is 
required to achieve optimal ligand binding to MC4 receptors (Kopanchuk et al. 
2005; Link et al. 2020). Furthermore, we have found that the ligand binding 
level to MC4 receptors in the presence of 1 mM Ca2+ could be further increased 
by the addition of a low amount of EDTA.  In the case of UTBC101, the 
specific ligand binding level was increased more than twice (230 ± 24%), 
whereas, in the case of UTBC102, the increase was moderate (126 ± 15%). The 
specific ligand binding level to MC4 receptors was considerably increased in 
these conditions without altering the affinity of the studied fluorescent ligands. 
Without calcium, EDTA did not induce ligand binding to MC4 receptors.  
 
 
 
Figure 6. Influence of Zn2+ and Cu2+ on the binding of UTBC101 to MC4 receptors 
in budded baculoviruses. The binding reaction was initiated by the addition of 0.8 nM 
MC4 receptors to 0.4 nM UTBC101. After 3 h, ZnSO4 (32 μM, blue triangles) or CuCl2 
(3 μM, orange circles) or the same amount of buffer (green circles) were added. The 
specific binding of ligands was characterized as the change in ∆FA values in time. Data 
are from a representative experiment of three independent experiments performed in 
duplicates. 
 
 
The observed EDTA effect indicated that some heavy metals could be involved 
in the inhibition of ligand binding to MC4 receptors. As a result of the deter-
mination of the metallic composition of the samples by ICP-MS, it was found 
that the receptor preparation contained in addition to buffer components (Na+, 
K+) also other metal ions in the micromolar range (Ca2+, Mg2+, Mn2+, Zn2+, Cu2+ ) 
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(Link et al. 2020). By studying the effect of these ions for UTBC101 binding in 
the presence 1 mM Ca2+, it was discovered that Mn2+ and Mg2+ had no 
significant effect on the level of specific ligand binding to MC4 receptors. 
Whereas, already 10 μM Zn2+ and 0.3 μM Cu2+ caused a significant inhibition 
of the level of specific ligand binding to MC4 receptors (Link et al. 2020). Zn2+ 
and Cu2+ caused a concentration-dependent inhibitory effect on the ligand 
binding to MC4 receptors, but also caused the dissociation of already formed 
complexes (Fig. 6). The effective concentration of these ions, causing inhibition 
of ligand binding to MC4 receptors was found to be in the physiologically 
relevant low micromolar range (Link et al. 2020). The effect of these metal ions 
was partially reversible upon the addition of excess EDTA. 
The rate and level of fluorescent ligand dissociation from MC4 receptors 
depended on the concentration of zinc and copper ions. The dissociation rate of 
UTBC101 was increased 20-fold by Zn2+ as the ion concentration was increased 
from 1 μM (koff = 0.006 ± 0.002 min-1; τ1/2 = 116 min) to 32 μM (koff = 0.12 ± 
0.06 min-1; τ1/2 = 6 min). Cu2+ caused a similar trend in the dissociation of 
UTBC101 over the concentration range of 0.1 μM to 10 μM. Although, Cu2+ 
induced a more complex dissociation than Zn2+, which induced one-phase 
exponential decay. Zinc and copper ions also induced the dissociation of 
UTBC102 and TAMRA-NDP-α-MSH from the complex with MC4 receptors at 
a similar concentration range (Link et al. 2020). The ligands’ dissociation rate 
dependence on ion concentration indicates that zinc and copper ions do not 
compete with the ligands for the orthosteric-binding site, but act as negative 
allosteric modulators. 
 
 
4.5. Modulation of the signal transduction of  
MC4 receptors by metal ions 
The effect of Zn2+ and Cu2+ on the biological activity of MC4 receptors was 
estimated by the change in cAMP accumulation in CHO-K1-MC4R cells using a 
FRET-based biosensor. Zn2+ caused a concentration-dependent increase in the 
accumulation of cAMP achieving almost the level of full agonists (93 ± 6%), 
whereas half of the maximal response was reached already at a 1.1 μM 
concentration (pEC50 = 5.95 ± 0.12) (Fig. 7, triangles). While Cu2+ induced a 
concentration-dependent biphasic change in cAMP accumulation, causing a 
marginal increase in cAMP levels at concentrations up to 1.5 μM (33 ± 9%) and 
a decrease in cAMP levels even below baseline at higher concentrations (Fig. 7, 
circles). A slight increase of cAMP accumulation was also seen in the naive 
CHO-K1 cells without MC4 receptors, but there was no decrease phase ob-
served. This indicated that only the inverse agonistic effect of Cu2+ could be 
mediated through MC4 receptors. As Zn2+ and Cu2+ can modulate the signal 
transduction of MC4 receptors at low micromolar levels, these ions may play a 
physiologically important role for these central nervous system receptors as 
endogenous agonists and inverse agonists, respectively. Upon neuronal stimula-
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tion, the free zinc concentration has been found to reach tens of micromolar in 
brain slices (and even higher at synapses), while free copper concentration is 
more tightly controlled (Thompson et al. 2000; Li et al. 2001b; Li et al. 2001a; 
Ueno et al. 2002; D’Ambrosi and Rossi 2015).  
 
 
 
 
Figure 7. Influence of Zn2+ and Cu2+ on the cAMP production in CHO-K1 cells ex-
pressing MC4 receptors. CHO-K1-MC4R cells expressing cAMP biosensor BacMam-
EpacH187 were treated with increasing concentrations of ZnSO4 (blue triangles) and 
CuCl2 (orange circles) for 0.5 h in the presence of 1 mM CaCl2. After that, fluorescence 
intensities were measured, and corresponding changes in ∆FRET values were calculated 
and normalized to the maximal NDP-α-MSH signal. Data are from a representative 
experiment of three independent experiments performed in triplicates. 
 
 
In vitro studies have shown that MC4 receptors exhibit a relatively high level of 
constitutive activity without agonistic ligands (Haskell-Luevano and Monck 
2001; Nijenhuis et al. 2001; Coll 2013). The reason for this constitutive activity 
may be Zn2+ ions, as zinc is often an ingredient of cell growth media (Bozym et 
al. 2008). Whereas, the presence of Cu2+ could influence the constitutive acti-
vity of MC4 receptors in an opposite manner when cell growth media are 
supplemented with serum or copper salts are added (Chaderjian et al. 2005; 
Qian et al. 2011). The level of constitutive activity of receptors is critical in 
functional studies, as it determines the behaviour of ligands as activators or 
inhibitors (Kenakin 2005; Bond and IJzerman 2006). It has been shown that an 
endogenous antagonist AgRP of MC4 receptors can behave as an inverse 
agonist for the cAMP pathway in case of elevated basal activity (Haskell-Lue-
vano and Monck 2001; Nijenhuis et al. 2001). Differences in its functionality 
have also been observed for the tetrapeptide His-DNal(2′)-Arg-Trp, which has 
behaved as an antagonist, but also as a partial agonist (Holder et al. 2002; Chen 
et al. 2006; Lensing et al. 2019). This was also observed in the current work, 
where previously described antagonist HS024 (Kask et al. 1998) behaved as a 
partial agonist (Fig. 4, diamonds).  
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The effect of Zn2+ and Cu2+ was studied on the signalling of the MC4 recep-
tor agonist NDP-α-MSH. Both ions influenced the level of basal and maximal 
cAMP accumulation but did not change the potency of NDP-α-MSH. This 
indicates that these ions function as allosteric modulators of MC4 receptors and 
not as orthosteric competitors. To estimate the allosteric nature of Zn2+, a Schild 
analysis was performed by studying the inhibition of the agonistic signal of Zn2+ 
by an MC4 receptor ligand HS024. HS024 inhibited the agonist signal of Zn2+ in 
a concentration-dependent manner, but the slope of the Schild plot was signi-
ficantly below unity (Link et al. 2020), which indicates again that zinc acts as 
an allosteric modulator of MC4 receptors. As a control, inhibition of the agonis-
tic signal of NDP-α-MSH by HS024 was also studied, resulting in a Schild plot 
with a slope close to unity, as it should be for an orthosteric ligand (Link et al. 
2020). As Cu2+ exhibits a biphasic signal, it was not possible to perform a 
classical Schild assay. However, it was shown that only the inverse agonistic 
signal of Cu2+ was blocked by HS024 in a concentration-dependent manner 
(Link et al. 2020), which confirms once again that these ions modulate the 
signal of MC4 receptors by suppressing its activity.  
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5. CONCLUSIONS 
The general aim of the study was to gain additional information about the ligand 
binding, allosteric modulation, and constitutive activity of melanocortin-4 
(MC4) receptors. The results that were acquired during this study enabled to 
make the following conclusions: 
 
• The developed budded baculovirus preparation of MC4 receptors and various 
fluorescent ligands enable high quality characterization of ligand binding to 
MC4 receptors using a homogeneous FA assay. The developed step-by-step 
FA method could be applicable to other GPCRs. 
• The slow dissociation of Cy3B-NDP-α-MSH (τ1/2 = 224 min) imposes limi-
tations for reaching reaction equilibrium. Therefore, novel fluorescent pepti-
des (UTBC101 and UTBC102) were synthesized. These Cy3B-labelled 
derivatives of SHU9119 exhibited high binding affinities towards MC4 
receptors, but rather different binding kinetics. The dissociation half-lives of 
UTBC101 and UTBC102 were 1.4 and 30 times shorter compared to Cy3B-
NDP-α-MSH, respectively.  
• It was shown that the equilibrium of competition reactions depends on the 
kinetic properties of labelled and unlabelled ligands and on the design of 
competition assay. Both UTBC101 and UTBC102 are suitable for the 
characterization of unlabelled ligand binding to MC4 receptors using FA 
assay. They complement each other in these studies, as UTBC102 enables to 
reach reaction equilibrium faster, and UTBC101 enables to cover a wider 
range of competitor potencies. 
• The CHO-K1 cell line stably expressing MC4 receptors was developed to 
assess the level of receptor activation via the detection of cAMP accumu-
lation using a FRET-based biosensor. It was shown that UTBC102 is a 
partial agonist in MC4 receptor-dependent cAMP accumulation, while 
UTBC101 exhibits only low partial agonistic properties. This offers new 
possibilities for the signal transduction studies of MC4 receptors, as there are 
no other previously reported fluorescent ligands with such functional pro-
perties.   
• It was shown that Ca2+ ions are essential for the high affinity ligand binding 
to MC4 receptors at millimolar concentrations, while Mg2+ and Mn2+ had an 
only negligible effect. At the same time, Zn2+ and Cu2+ ions inhibited the 
ligand binding already at physiologically relevant low micromolar con-
centrations in the presence of Ca2+. 
• Zn2+ and Cu2+ ions inhibited the formation of MC4 receptor-ligand comple-
xes as well as induced dissociation of already formed complexes. As the 
dissociation rate of ligands depended on the concentration of Zn2+ and Cu2+, 
it was proposed that these ions act as negative allosteric modulators of ligand 
binding to MC4 receptors. 
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• Zn2+ and Cu2+ have different effects on the constitutive activity of MC4 
receptors in the cAMP pathway. Low micromolar concentrations of Zn2+ 
cause activation of MC4 receptors up to full agonistic levels, whereas Cu2+ 
ions suppress the activity even below baseline levels. This indicates that 
these ions could play a physiologically relevant role as endogenous agonists 
or inverse agonists of MC4 receptors, respectively. In addition, in cellular 
studies, it should be taken into account that Zn2+ and Cu2+ ions are common 
ingredients of the cell growth media.  
• The FA-based ligand binding and FRET-based functional assays that were 
further developed in this study have already been successfully applied for the 
characterization of several other GPCRs. As both zinc and copper are 
endogenous ions in the body, their involvement in the regulation of signal 
transduction with other GPCRs requires further studies.  
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SUMMARY IN ESTONIAN 
Melanokortiin-4 retseptorite ligandiga seostumine, 
allosteeriline modulatsioon ja konstitutiivne aktiivsus 
Melanokortiin-4 (MC4) retseptorid on peamiselt kesknärvisüsteemis leiduvad 
G-valguga seotud retseptorid, mis reguleerivad kehas mitmeid olulisi funktsioone, 
nagu energia homeostaas, toitumine ja seksuaalsed funktsioonid. Seetõttu paku-
vad need retseptorid ravimiarendusfirmadele suurt huvi. Nende plasmamemb-
raanis asuvate retseptorite poolt vahendatav signaaliülekanne rakku on keeruline 
dünaamiline protsess, mille kõiki iseärasusi senini veel täpselt ei mõisteta.  
Käesoleva doktoritöö üldiseks eesmärgiks oli saada lisateavet MC4 retsep-
torite ligandi seostumise, allosteerilise modulatsiooni ja konstitutiivse aktiivsuse 
kohta. Töö üldise eesmärgi saavutamiseks püstitati mitu konkreetset ülesannet:  
• Fluorestsentsanisotroopia (FA) baasil põhineva katsesüsteemi arenda-
mine, kasutades pungunud bakuloviiruste preparaati uuritavate retsepto-
rite allikana, et iseloomustada ligandi seostumiskineetikat MC4 retsep-
toritele. 
• Uudsete fluorestsentsligandide arendamine ja rakendamine ligandi seos-
tumise iseloomustamiseks MC4 retseptoritele. 
• MC4 retseptorite signaaliülekande uurimine FRET-il põhineva biosen-
sori katsesüsteemi abil, mis tuvastab sekundaarse virgatsaine cAMP 
kontsentratsiooni rakus. Antud retseptorite konstitutiivse aktiivsuse ja 
selle inhibeerimise määramine. 
• Erinevate metalliioonide mõju iseloomustamine MC4 retseptorite ligan-
di seostumisele ja cAMP tootmise aktiveerimisele. 
 
Kokkuvõtvalt võimaldasid antud töö tulemused jõuda järgmiste järeldusteni: 
• MC4 retseporeid ekspresseerivad pungunud bakuloviirused võimal-
davad kõrgkvaliteedilist ligandi seostumise määramist nendele retsepo-
ritele FA katsesüsteemis. 
• Cy3B-NDP-α-MSH aeglane dissotsiatsioon (τ1/2 = 224 min) seab piiran-
gud MC4 retseptoritega seostumisreaktsiooni tasakaalu saavutamisele. 
Seetõttu sünteesiti uued Cy3B-märgistatud fluorestsentspeptiidid 
(UTBC101 ja UTBC102), mis on SHU9119 derivaadid. Mõlematel on 
kõrge seostumisafiinsus MC4 retseptoritele, kuid üsna erinev seostumis-
kineetika. UTBC101-l on 1,4 korda ja UTBC102-l on 30 korda lühem 
dissotsiatsiooni pooleluiga võrreldes Cy3B-NDP-α-MSH-ga. 
• Konkureerimisreaktsioonide tasakaal sõltub märgistatud ja märgista-
mata ligandide kineetilistest omadustest ja katse ülesehitusest. Mõle-
mad, nii UTBC101 kui ka UTBC102, sobivad märgistamata ligandide 
seostumise iseloomistamiseks MC4 retseptoritele kasutades FA katset. 
Seejuures nad täiendavad üksteist, kuna UTBC102-ga saavutatakse 
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tasakaal kiiremini, aga UTBC101 võimaldab iseloomustada kõrgema 
afiinsusega märgistamata ligande. 
• MC4 retseptoreid stabiilselt ekspresseeriv CHO-K1 rakuliin arendati välja 
selleks, et hinnata retseptorite aktivatsioonitaset cAMP tootmise kaudu, 
kasutades FRET-il põhinevat biosensorit. Selle katsesüsteemi abil 
näidati, et UTBC102 käitub kui osaline agonist, samas kui UTBC101 
omab ainult väga madalat osalist agonistlikku aktiivsust. See pakub uusi 
võimalusi MC4 retseptorite signaaliülekande uurimiseks, kuna teisi 
selliste funktsionaalsete omadustega fluorestsentsligande teadaolevalt 
pole. 
• Millimolaarses kontsentratsioonis Ca2+ ioonid on hädavajalikud suure 
afiinsusega ligandi seostumiseks MC4 retseptoritega, samas kui Mg2+ ja 
Mn2+ olulist mõju ei oma. Seevastu Zn2+ ja Cu2+ ioonid pärssisid ligandi 
seostumist juba füsioloogiliselt olulistel mikromolaarsetel kontsentrat-
sioonidel Ca2+ ioonide juureolekul. 
• Zn2+ ja Cu2+ ioonid pidurdasid MC4 retseptor-ligand komplekside moo-
dustumist, samuti algatasid juba moodustunud komplekside dissotsiat-
siooni. Nende ioonide kontsentratsioonist sõltuv retseptor-ligand 
komplekside dissotsiatsioonikiirus viitab sellele, et Zn2+ ja Cu2+ ioonid 
on MC4 retseptorite negatiivsed allosteerilised modulaatorid. 
• Zn2+ ja Cu2+ avaldavad erinevat mõju MC4 retseptorite konstitutiivsele 
aktiivsusele cAMP signaalrajal. Madal mikromolaarne Zn2+ aktiveerib 
MC4 retseptoreid pea täisagonistilikul tasemele, samas kui Cu2+ vähen-
dab retseptorite aktviisust isegi alla baastaset. Seega võivad ioonid 
toimida MC4 retseptorite endogeensete agonistide või pöördagonis-
tidena. Seda tuleks arvestada ka rutiinsete rakukatsete läbiviimisel, kuna 
need ioonid on sageli rakusöötmete komponendite hulgas. 
 
Antud töö tulemused on rakendatavad ka teiste retseptorsüsteemide uurimiseks, 
sest järjest enam kasutatakse FA-l ja FRET-biosensoril põhinevaid katse-
süsteeme. Lisaks on selles töös näidatud endogeensete metalliioonide mõju 
uurimine oluline ka teiste GPCR-ide signaaliülekannete puhul, kuna need 
ioonid esinevad nii kudedes kui ka rakukultuuri kasvulahustes. 
 
 
48 
ACKNOWLEDGEMENTS 
The research at hand was financed by the Estonian Ministry of Education and 
Science (IUT20-17 and PSG230) and by the European Union through the Euro-
pean Regional Development Fund (EU48695).  
Firstly, I am extremely glad that I decided to knock on the door of Professor 
Ago Rinken to join his research group. Thanks to the opportunity that he gave 
me, I found the research field that has kept me fascinated for years. Professor 
Rinken has thought me the importance of communication between scientists 
amongst different fields by encouraging me to attend and organize conferences 
and learn through teaching. 
Secondly, I would like to express my deepest gratitude to my supervisors 
Sergei Kopanchuk and Professor Rinken for their patience to shape me into a 
scientist. Sergei has brought invaluable contribution to the present thesis, as he 
always found a way around a problem when I felt stuck. He is an excellent role 
model of a great scientist and it has been a privilege to learn from him.  
I am also very grateful to Santa Veiksina, Tõnis Laasfeld, Maris-Johanna 
Tahk, Päärn Paiste and my student Anne Lille, who have all contributed to this 
work and participated in constructive scientific discussions. I would also like to 
thank my colleagues Anni Allikalt, Olga Mazina, Kadri Ligi and Darja Lovõ-
gina for their scientific input and for keeping things running smoothly in our 
research group.  
I would like to express my deep gratitude for the Head of Tartu Laboratory 
of Health Board Mari Reinik for offering the possibility to become a specialist 
in the field of pesticide analysis and for enabling me to work with flexible hours 
to proceed with my doctoral studies. 
I want to thank my family – you are my strength. Mom, thank you for being 
an excellent role model showing me how to work through tough times. Brother, 
thank you for being there when I felt like giving up. I would also like to thank 
Karl Lepp for his love and support. You have been pillars to lean on during my 
time of studies and writing of the thesis.  
This journey has been very challenging for me and I hope I have become a 
better person and chemist in the process. I am extremely grateful for your 
valuable help and time. Thank you all! 
 
 
  
 
 
PUBLICATIONS 
  
CURRICULUM VITAE 
Name: Reet Link 
Date of birth: December 23, 1988
Citizenship: Estonian 
Address: University of Tartu, Institute of Chemistry,  
Ravila 14a, 50411, Tartu, Estonia
E-mail: reetlink@gmail.com 
 
Education: 
2014–… University of Tartu, PhD student in chemistry
2012–2014 University of Tartu, MSc in chemistry
2009–2012 University of Tartu, BSc in chemistry
2005–2008 Tallinn Arte Gymnasium 
 
Professional employment:  
2015–… Tartu Laboratory of Health Board, senior specialist 
2018–2019 University of Tartu, Institute of Chemistry, chemist 
2011–2015 University of Tartu, Science School, Chemistry Workshop, 
tutor 
 
Professional organization:  
2016–… Member of the Estonian Biochemistry Society
2017–2020 Member of the European Society for Neurochemistry 
2017–2020 Member of the International Society for Neurochemistry 
 
Scientific publications:  
1. Veiksina, S., Tahk, M. J., Laasfeld, T., Link, R., Kopanchuk, S., Rinken, A. 
(2020) Fluorescence anisotropy-based assay for characterization of ligand 
binding dynamics to GPCRs. The case of Cy3B-labelled ligands binding to 
MC4 receptors in budded baculoviruses. In press in G Protein-Coupled 
Receptor Screening Assays. 
2. Link, R., Veiksina, S., Tahk, M. J., Laasfeld, T., Paiste, P., Kopanchuk, S., 
Rinken, A. (2020). The constitutive activity of melanocortin‐4 receptors in 
cAMP pathway is allosterically modulated by zinc and copper ions. Journal 
of Neurochemistry 153, 346–361. doi.org/10.1007/978-1-4939-2336-6_3 
3. Link R., Veiksina S., Rinken A., Kopanchuk S. (2017) Characterization of 
ligand binding to melanocortin 4 receptors using fluorescent peptides with 
improved kinetic properties. European Journal of Pharmacology 799, 58–
66. doi.org/10.1016/j.ejphar.2017.01.040 
4. Veiksina, S., Kopanchuk, S., Mazina, O., Link, R., Lille, A., Rinken, A. 
(2015). Homogeneous fluorescence anisotropy-based assay for characteri-
zation of ligand binding dynamics to GPCRs in budded baculoviruses: The 
case of Cy3B-NDP-α-MSH binding to MC4 receptors. In G Protein-
Coupled Receptor Screening Assays, pp. 37–50. Springer New York, New 
York, NY. doi.org/10.1007/978-1-4939-2336-6_3 
97 
ELULOOKIRJELDUS 
Nimi: Reet Link
Sünniaeg: 23. detsember 1988
Kodakondsus: eesti 
Aaddress: Tartu Ülikool, Keemia Instituut 
Ravila 14a, 50411, Tartu, Eesti
E-post: reetlink@gmail.com 
 
Haridus: 
2014–… Tartu Ülikool, doktoriõpe keemias
2012–2014 Tartu Ülikool, MSc keemias
2009–2012 Tartu Ülikool, BSc keemias
2005–2008 Tallinna Arte Gümnaasium 
 
Erialane teenistuskäik:  
2015–… Terviseamet Tartu labor, vanemspetsialist
2018–2019 Tartu Ülikool, Keemia Instituut, keemik
2011–2015 Tartu Ülikool, Teaduskool, Keemiaõpikoda, juhendaja 
 
Teadusorganisatsioonid:  
2016–… Eesti Biokeemia Seltsi liige
2017–2020 Euroopa Neurokeemia Seltsi liige
2017–2020 Rahvusvahelise Neurokeemia Seltsi liige 
 
Teaduspublikatsioonid:  
1. Veiksina, S., Tahk, M. J., Laasfeld, T., Link, R., Kopanchuk, S., Rinken, A. 
(2020) Fluorescence anisotropy-based assay for characterization of ligand 
binding dynamics to GPCRs. The case of Cy3B-labelled ligands binding to 
MC4 receptors in budded baculoviruses. In press in G Protein-Coupled 
Receptor Screening Assays. 
2. Link, R., Veiksina, S., Tahk, M. J., Laasfeld, T., Paiste, P., Kopanchuk, S., 
Rinken, A. (2020). The constitutive activity of melanocortin‐4 receptors in 
cAMP pathway is allosterically modulated by zinc and copper ions. Journal 
of Neurochemistry 153, 346–361. doi.org/10.1007/978-1-4939-2336-6_3 
3. Link R., Veiksina S., Rinken A., Kopanchuk S. (2017) Characterization of 
ligand binding to melanocortin 4 receptors using fluorescent peptides with 
improved kinetic properties. European Journal of Pharmacology 799, 58–
66. doi.org/10.1016/j.ejphar.2017.01.040 
4. Veiksina, S., Kopanchuk, S., Mazina, O., Link, R., Lille, A., Rinken, A. 
(2015). Homogeneous fluorescence anisotropy-based assay for characteri-
zation of ligand binding dynamics to GPCRs in budded baculoviruses: The 
case of Cy3B-NDP-α-MSH binding to MC4 receptors. In G Protein-Coupled 
Receptor Screening Assays, pp. 37–50. Springer New York, New York, NY. 
doi.org/10.1007/978-1-4939-2336-6_3 
 
98 
DISSERTATIONES CHIMICAE  
UNIVERSITATIS TARTUENSIS 
1. Toomas Tamm. Quantum-chemical simulation of solvent effects. Tartu, 
1993, 110 p. 
2. Peeter Burk. Theoretical study of gas-phase acid-base equilibria. Tartu, 
1994, 96 p. 
3. Victor Lobanov. Quantitative structure-property relationships in large 
descriptor spaces. Tartu, 1995, 135 p. 
4. Vahur Mäemets. The 17O and 1H nuclear magnetic resonance study of 
H2O in individual solvents and its charged clusters in aqueous solutions of 
electrolytes. Tartu, 1997, 140 p. 
5.  Andrus Metsala. Microcanonical rate constant in nonequilibrium distribu-
tion of vibrational energy and in restricted intramolecular vibrational 
energy redistribution on the basis of slater’s theory of unimolecular re-
actions. Tartu, 1997, 150 p. 
6. Uko Maran. Quantum-mechanical study of potential energy surfaces in 
different environments. Tartu, 1997, 137 p. 
7. Alar Jänes. Adsorption of organic compounds on antimony, bismuth and 
cadmium electrodes. Tartu, 1998, 219 p. 
8. Kaido Tammeveski. Oxygen electroreduction on thin platinum films and 
the electrochemical detection of superoxide anion. Tartu, 1998, 139 p. 
9. Ivo Leito. Studies of Brønsted acid-base equilibria in water and non-
aqueous media. Tartu, 1998, 101 p. 
10.  Jaan Leis. Conformational dynamics and equilibria in amides. Tartu, 1998, 
131 p. 
11.  Toonika Rinken. The modelling of amperometric biosensors based on oxi-
doreductases. Tartu, 2000, 108 p. 
12. Dmitri Panov. Partially solvated Grignard reagents. Tartu, 2000, 64 p.  
13. Kaja Orupõld. Treatment and analysis of phenolic wastewater with micro-
organisms. Tartu, 2000, 123 p. 
14. Jüri Ivask. Ion Chromatographic determination of major anions and 
cations in polar ice core. Tartu, 2000, 85 p. 
15. Lauri Vares. Stereoselective Synthesis of Tetrahydrofuran and Tetra-
hydropyran Derivatives by Use of Asymmetric Horner-Wadsworth- 
Emmons and Ring Closure Reactions. Tartu, 2000, 184 p.  
16. Martin Lepiku. Kinetic aspects of dopamine D2 receptor interactions with 
specific ligands. Tartu, 2000, 81 p. 
17. Katrin Sak. Some aspects of ligand specificity of P2Y receptors. Tartu, 
2000, 106 p. 
18. Vello Pällin. The role of solvation in the formation of iotsitch complexes. 
Tartu, 2001, 95 p. 
19.  Katrin Kollist. Interactions between polycyclic aromatic compounds and 
humic substances. Tartu, 2001, 93 p. 
99 
100 
20. Ivar Koppel. Quantum chemical study of acidity of strong and superstrong 
Brønsted acids. Tartu, 2001, 104 p. 
21. Viljar Pihl. The study of the substituent and solvent effects on the acidity 
of OH and CH acids. Tartu, 2001, 132 p. 
22. Natalia Palm. Specification of the minimum, sufficient and significant set 
of descriptors for general description of solvent effects. Tartu, 2001, 134 p. 
23. Sulev Sild. QSPR/QSAR approaches for complex molecular systems. 
Tartu, 2001, 134 p. 
24. Ruslan Petrukhin. Industrial applications of the quantitative structure-
property relationships. Tartu, 2001, 162 p. 
25. Boris V. Rogovoy. Synthesis of (benzotriazolyl)carboximidamides and their 
application in relations with N- and S-nucleophyles. Tartu, 2002, 84 p. 
26. Koit Herodes. Solvent effects on UV-vis absorption spectra of some 
solvatochromic substances in binary solvent mixtures: the preferential 
solvation model. Tartu, 2002, 102 p. 
27. Anti Perkson. Synthesis and characterisation of nanostructured carbon. 
Tartu, 2002, 152 p. 
28. Ivari Kaljurand. Self-consistent acidity scales of neutral and cationic 
Brønsted acids in acetonitrile and tetrahydrofuran. Tartu, 2003, 108 p. 
29. Karmen Lust. Adsorption of anions on bismuth single crystal electrodes. 
Tartu, 2003, 128 p. 
30. Mare Piirsalu. Substituent, temperature and solvent effects on the alkaline 
hydrolysis of substituted phenyl and alkyl esters of benzoic acid. Tartu, 
2003, 156 p. 
31. Meeri Sassian. Reactions of partially solvated Grignard reagents. Tartu, 
2003, 78 p. 
32. Tarmo Tamm. Quantum chemical modelling of polypyrrole. Tartu, 2003. 
100 p. 
33. Erik Teinemaa. The environmental fate of the particulate matter and 
organic pollutants from an oil shale power plant. Tartu, 2003. 102 p. 
34. Jaana Tammiku-Taul. Quantum chemical study of the properties of 
Grignard reagents. Tartu, 2003. 120 p. 
35. Andre Lomaka. Biomedical applications of predictive computational  
chemistry. Tartu, 2003. 132 p. 
36. Kostyantyn Kirichenko. Benzotriazole – Mediated Carbon–Carbon Bond 
Formation. Tartu, 2003. 132 p. 
37. Gunnar Nurk. Adsorption kinetics of some organic compounds on bis-
muth single crystal electrodes. Tartu, 2003, 170 p. 
38. Mati Arulepp. Electrochemical characteristics of porous carbon materials 
and electrical double layer capacitors. Tartu, 2003, 196 p. 
39. Dan Cornel Fara. QSPR modeling of complexation and distribution of 
organic compounds. Tartu, 2004, 126 p. 
40. Riina Mahlapuu. Signalling of galanin and amyloid precursor protein 
through adenylate cyclase. Tartu, 2004, 124 p. 
101 
41. Mihkel Kerikmäe. Some luminescent materials for dosimetric applications 
and physical research. Tartu, 2004, 143 p. 
42. Jaanus Kruusma. Determination of some important trace metal ions in 
human blood. Tartu, 2004, 115 p. 
43. Urmas Johanson. Investigations of the electrochemical properties of poly-
pyrrole modified electrodes. Tartu, 2004, 91 p. 
44. Kaido Sillar. Computational study of the acid sites in zeolite ZSM-5. 
Tartu, 2004, 80 p. 
45. Aldo Oras. Kinetic aspects of dATPαS interaction with P2Y1 receptor. 
Tartu, 2004, 75 p. 
46. Erik Mölder. Measurement of the oxygen mass transfer through the air-
water interface. Tartu, 2005, 73 p.  
47. Thomas Thomberg. The kinetics of electroreduction of peroxodisulfate 
anion on cadmium (0001) single crystal electrode. Tartu, 2005, 95 p. 
48. Olavi Loog. Aspects of condensations of carbonyl compounds and their 
imine analogues. Tartu, 2005, 83 p.  
49. Siim Salmar. Effect of ultrasound on ester hydrolysis in aqueous ethanol. 
Tartu, 2006, 73 p.  
50. Ain Uustare. Modulation of signal transduction of heptahelical receptors 
by other receptors and G proteins. Tartu, 2006, 121 p. 
51. Sergei Yurchenko. Determination of some carcinogenic contaminants in 
food. Tartu, 2006, 143 p.  
52. Kaido Tämm. QSPR modeling of some properties of organic compounds. 
Tartu, 2006, 67 p.  
53. Olga Tšubrik. New methods in the synthesis of multisubstituted hydra-
zines. Tartu. 2006, 183 p.  
54. Lilli Sooväli. Spectrophotometric measurements and their uncertainty in 
chemical analysis and dissociation constant measurements. Tartu, 2006,  
125 p. 
55. Eve Koort. Uncertainty estimation of potentiometrically measured ph and 
pKa values. Tartu, 2006, 139 p.  
56. Sergei Kopanchuk. Regulation of ligand binding to melanocortin receptor 
subtypes. Tartu, 2006, 119 p.  
57. Silvar Kallip. Surface structure of some bismuth and antimony single 
crystal electrodes. Tartu, 2006, 107 p. 
58. Kristjan Saal. Surface silanization and its application in biomolecule 
coupling. Tartu, 2006, 77 p. 
59. Tanel Tätte. High viscosity Sn(OBu)4 oligomeric concentrates and their 
applications in technology. Tartu, 2006, 91 p. 
60. Dimitar Atanasov Dobchev. Robust QSAR methods for the prediction of 
properties from molecular structure. Tartu, 2006, 118 p.  
61.  Hannes Hagu. Impact of ultrasound on hydrophobic interactions in 
solutions. Tartu, 2007, 81 p. 
62. Rutha Jäger. Electroreduction of peroxodisulfate anion on bismuth 
electrodes. Tartu, 2007, 142 p. 
102 
63. Kaido Viht. Immobilizable bisubstrate-analogue inhibitors of basophilic 
protein kinases: development and application in biosensors. Tartu, 2007,  
88 p. 
64. Eva-Ingrid Rõõm. Acid-base equilibria in nonpolar media. Tartu, 2007, 
156 p. 
65. Sven Tamp. DFT study of the cesium cation containing complexes relevant 
to the cesium cation binding by the humic acids. Tartu, 2007, 102 p. 
66. Jaak Nerut. Electroreduction of hexacyanoferrate(III) anion on Cadmium 
(0001) single crystal electrode. Tartu, 2007, 180 p.  
67. Lauri Jalukse. Measurement uncertainty estimation in amperometric 
dissolved oxygen concentration measurement. Tartu, 2007, 112 p. 
68. Aime Lust. Charge state of dopants and ordered clusters formation in 
CaF2:Mn and CaF2:Eu luminophors. Tartu, 2007, 100 p. 
69. Iiris Kahn. Quantitative Structure-Activity Relationships of environ-
mentally relevant properties. Tartu, 2007, 98 p. 
70. Mari Reinik. Nitrates, nitrites, N-nitrosamines and polycyclic aromatic 
hydrocarbons in food: analytical methods, occurrence and dietary intake. 
Tartu, 2007, 172 p. 
71. Heili Kasuk. Thermodynamic parameters and adsorption kinetics of orga-
nic compounds forming the compact adsorption layer at Bi single crystal 
electrodes. Tartu, 2007, 212 p. 
72. Erki Enkvist. Synthesis of adenosine-peptide conjugates for biological 
applications. Tartu, 2007, 114 p.  
73. Svetoslav Hristov Slavov. Biomedical applications of the QSAR approach. 
Tartu, 2007, 146 p. 
74. Eneli Härk. Electroreduction of complex cations on electrochemically 
polished Bi(hkl) single crystal electrodes. Tartu, 2008, 158 p.  
75. Priit Möller. Electrochemical characteristics of some cathodes for medium 
temperature solid oxide fuel cells, synthesized by solid state reaction 
technique. Tartu, 2008, 90 p.  
76. Signe Viggor. Impact of biochemical parameters of genetically different 
pseudomonads at the degradation of phenolic compounds. Tartu, 2008, 122 p. 
77. Ave Sarapuu. Electrochemical reduction of oxygen on quinone-modified 
carbon electrodes and on thin films of platinum and gold. Tartu, 2008,  
134 p.  
78. Agnes Kütt. Studies of acid-base equilibria in non-aqueous media. Tartu, 
2008, 198 p.  
79. Rouvim Kadis. Evaluation of measurement uncertainty in analytical che-
mistry: related concepts and some points of misinterpretation. Tartu, 2008, 
118 p. 
80.  Valter Reedo. Elaboration of IVB group metal oxide structures and their 
possible applications. Tartu, 2008, 98 p. 
81.  Aleksei Kuznetsov. Allosteric effects in reactions catalyzed by the cAMP-
dependent protein kinase catalytic subunit. Tartu, 2009, 133 p. 
103 
82. Aleksei Bredihhin. Use of mono- and polyanions in the synthesis of 
multisubstituted hydrazine derivatives. Tartu, 2009, 105 p. 
83.  Anu Ploom. Quantitative structure-reactivity analysis in organosilicon 
chemistry. Tartu, 2009, 99 p.  
84. Argo Vonk. Determination of adenosine A2A- and dopamine D1 receptor-
specific modulation of adenylate cyclase activity in rat striatum. Tartu, 
2009, 129 p. 
85.  Indrek Kivi. Synthesis and electrochemical characterization of porous 
cathode materials for intermediate temperature solid oxide fuel cells. 
Tartu, 2009, 177 p.  
86. Jaanus Eskusson. Synthesis and characterisation of diamond-like carbon 
thin films prepared by pulsed laser deposition method. Tartu, 2009, 117 p. 
87. Marko Lätt. Carbide derived microporous carbon and electrical double 
layer capacitors. Tartu, 2009, 107 p. 
88. Vladimir Stepanov. Slow conformational changes in dopamine transpor-
ter interaction with its ligands. Tartu, 2009, 103 p.  
89. Aleksander Trummal. Computational Study of Structural and Solvent 
Effects on Acidities of Some Brønsted Acids. Tartu, 2009, 103 p. 
90.  Eerold Vellemäe. Applications of mischmetal in organic synthesis. Tartu, 
2009, 93 p. 
91.  Sven Parkel. Ligand binding to 5-HT1A receptors and its regulation by 
Mg2+ and Mn2+. Tartu, 2010, 99 p. 
92.  Signe Vahur. Expanding the possibilities of ATR-FT-IR spectroscopy in 
determination of inorganic pigments. Tartu, 2010, 184 p. 
93. Tavo Romann. Preparation and surface modification of bismuth thin 
film, porous, and microelectrodes. Tartu, 2010, 155 p. 
94.  Nadežda Aleksejeva. Electrocatalytic reduction of oxygen on carbon 
nanotube-based nanocomposite materials. Tartu, 2010, 147 p.  
95.  Marko Kullapere. Electrochemical properties of glassy carbon, nickel 
and gold electrodes modified with aryl groups. Tartu, 2010, 233 p. 
96. Liis Siinor. Adsorption kinetics of ions at Bi single crystal planes from 
aqueous electrolyte solutions and room-temperature ionic liquids. Tartu, 
2010, 101 p. 
97.   Angela Vaasa. Development of fluorescence-based kinetic and binding 
assays for characterization of protein kinases and their inhibitors. Tartu 
2010, 101 p. 
98. Indrek Tulp. Multivariate analysis of chemical and biological properties. 
Tartu 2010, 105 p. 
99.  Aare Selberg. Evaluation of environmental quality in Northern Estonia 
by the analysis of leachate. Tartu 2010, 117 p. 
100. Darja Lavõgina. Development of protein kinase inhibitors based on 
adenosine analogue-oligoarginine conjugates. Tartu 2010, 248 p. 
101. Laura Herm. Biochemistry of dopamine D2 receptors and its association 
with motivated behaviour. Tartu 2010, 156 p. 
104 
102. Terje Raudsepp. Influence of dopant anions on the electrochemical pro-
perties of polypyrrole films. Tartu 2010, 112 p.  
103.  Margus Marandi. Electroformation of Polypyrrole Films: In-situ AFM 
and STM Study. Tartu 2011, 116 p. 
104. Kairi Kivirand. Diamine oxidase-based biosensors: construction and 
working principles. Tartu, 2011, 140 p. 
105. Anneli Kruve. Matrix effects in liquid-chromatography electrospray 
mass-spectrometry. Tartu, 2011, 156 p. 
106. Gary Urb. Assessment of environmental impact of oil shale fly ash from 
PF and CFB combustion.  Tartu, 2011, 108 p. 
107. Nikita Oskolkov. A novel strategy for peptide-mediated cellular delivery 
and induction of endosomal escape. Tartu, 2011, 106 p. 
108. Dana Martin. The QSPR/QSAR approach for the prediction of properties of 
fullerene derivatives. Tartu, 2011, 98 p. 
109.  Säde Viirlaid. Novel glutathione analogues and their antioxidant activity. 
Tartu, 2011, 106 p. 
110.  Ülis Sõukand. Simultaneous adsorption of Cd2+, Ni2+, and Pb2+ on peat. 
Tartu, 2011, 124 p. 
111. Lauri Lipping. The acidity of strong and superstrong Brønsted acids, an 
outreach for the “limits of growth”: a quantum chemical study. Tartu, 
2011, 124 p. 
112. Heisi Kurig. Electrical double-layer capacitors based on ionic liquids as 
electrolytes. Tartu, 2011, 146 p. 
113. Marje Kasari. Bisubstrate luminescent probes, optical sensors and 
affinity adsorbents for measurement of active protein kinases in biological 
samples. Tartu, 2012, 126 p. 
114. Kalev Takkis. Virtual screening of chemical databases for bioactive 
molecules. Tartu, 2012, 122 p. 
115. Ksenija Kisseljova. Synthesis of aza-β3-amino acid containing peptides 
and kinetic study of their phosphorylation by protein kinase A. Tartu, 
2012, 104 p. 
116. Riin Rebane. Advanced method development strategy for derivatization 
LC/ESI/MS. Tartu, 2012, 184 p. 
117. Vladislav Ivaništšev. Double layer structure and adsorption kinetics of 
ions at metal electrodes in room temperature ionic liquids. Tartu, 2012, 
128 p. 
118.  Irja Helm. High accuracy gravimetric Winkler method for determination 
of dissolved oxygen. Tartu, 2012, 139 p. 
119. Karin Kipper. Fluoroalcohols as Components of LC-ESI-MS Eluents: 
Usage and Applications. Tartu, 2012, 164 p. 
120. Arno Ratas. Energy storage and transfer in dosimetric luminescent 
materials. Tartu, 2012, 163 p. 
121.  Reet Reinart-Okugbeni. Assay systems for characterisation of subtype-
selective binding and functional activity of ligands on dopamine receptors. 
Tartu, 2012, 159 p. 
105 
122.  Lauri Sikk. Computational study of the Sonogashira cross-coupling 
reaction. Tartu, 2012, 81 p. 
123. Karita Raudkivi. Neurochemical studies on inter-individual differences 
in affect-related behaviour of the laboratory rat. Tartu, 2012, 161 p. 
124.  Indrek Saar. Design of GalR2 subtype specific ligands: their role in 
depression-like behavior and feeding regulation. Tartu, 2013, 126 p. 
125. Ann Laheäär. Electrochemical characterization of alkali metal salt based 
non-aqueous electrolytes for supercapacitors. Tartu, 2013, 127 p.  
126.  Kerli Tõnurist. Influence of electrospun separator materials properties on 
electrochemical performance of electrical double-layer capacitors. Tartu, 
2013, 147 p. 
127.  Kaija Põhako-Esko. Novel organic and inorganic ionogels: preparation 
and characterization. Tartu, 2013, 124 p.  
128.  Ivar Kruusenberg. Electroreduction of oxygen on carbon nanomaterial-
based catalysts. Tartu, 2013, 191 p. 
129. Sander Piiskop. Kinetic effects of ultrasound in aqueous acetonitrile 
solutions. Tartu, 2013, 95 p. 
130.  Ilona Faustova. Regulatory role of L-type pyruvate kinase N-terminal 
domain. Tartu, 2013, 109 p. 
131. Kadi Tamm. Synthesis and characterization of the micro-mesoporous 
anode materials and testing of the medium temperature solid oxide fuel 
cell single cells. Tartu, 2013, 138 p.  
132.  Iva Bozhidarova Stoyanova-Slavova. Validation of QSAR/QSPR for 
regulatory purposes. Tartu, 2013, 109 p. 
133. Vitali Grozovski. Adsorption of organic molecules at single crystal 
electrodes studied by in situ STM method. Tartu, 2014, 146 p. 
134. Santa Veikšina. Development of assay systems for characterisation of 
ligand binding properties to melanocortin 4 receptors. Tartu, 2014, 151 p. 
135. Jüri Liiv. PVDF (polyvinylidene difluoride) as material for active 
element  of twisting-ball displays. Tartu, 2014, 111 p. 
136. Kersti Vaarmets. Electrochemical and physical characterization of 
pristine and activated molybdenum carbide-derived carbon electrodes for 
the oxygen electroreduction reaction. Tartu, 2014, 131 p. 
137. Lauri Tõntson. Regulation of G-protein subtypes by receptors, guanine 
nucleotides and Mn2+. Tartu, 2014, 105 p. 
138. Aiko Adamson. Properties of amine-boranes and phosphorus analogues 
in the gas phase. Tartu, 2014, 78 p. 
139. Elo Kibena. Electrochemical grafting of glassy carbon, gold, highly 
oriented pyrolytic graphite and chemical vapour deposition-grown graphene 
electrodes by diazonium reduction method. Tartu, 2014, 184 p.  
140.  Teemu Näykki. Novel Tools for Water Quality Monitoring – From Field 
to Laboratory. Tartu, 2014, 202 p. 
141.  Karl Kaupmees. Acidity and basicity in non-aqueous media: importance 
of solvent properties and purity. Tartu, 2014, 128 p. 
106 
142. Oleg Lebedev. Hydrazine polyanions: different strategies in the synthesis 
of heterocycles. Tartu, 2015, 118 p. 
143.  Geven Piir. Environmental risk assessment of chemicals using QSAR 
methods. Tartu, 2015, 123 p. 
144.   Olga Mazina. Development and application of the biosensor assay for 
measurements of cyclic adenosine monophosphate in studies of G protein-
coupled receptor signalinga. Tartu, 2015, 116 p. 
145.  Sandip Ashokrao Kadam. Anion receptors: synthesis and accurate 
binding measurements. Tartu, 2015, 116 p. 
146.  Indrek Tallo. Synthesis and characterization of new micro-mesoporous 
carbide derived carbon materials for high energy and power density 
electrical double layer capacitors. Tartu, 2015, 148 p. 
147.  Heiki Erikson. Electrochemical reduction of oxygen on nanostructured 
palladium and gold catalysts. Tartu, 2015, 204 p. 
148.  Erik Anderson. In situ Scanning Tunnelling Microscopy studies of the 
interfacial structure between Bi(111) electrode and a room temperature 
ionic liquid. Tartu, 2015, 118 p. 
149.  Girinath G. Pillai. Computational Modelling of Diverse Chemical, Bio-
chemical and Biomedical Properties. Tartu, 2015, 140 p. 
150. Piret Pikma. Interfacial structure and adsorption of organic compounds at 
Cd(0001) and Sb(111) electrodes from ionic liquid and aqueous 
electrolytes: an in situ STM study. Tartu, 2015, 126 p. 
151. Ganesh babu Manoharan. Combining chemical and genetic approaches 
for photoluminescence assays of protein kinases. Tartu, 2016, 126 p. 
152. Carolin Siimenson. Electrochemical characterization of halide ion 
adsorption from liquid mixtures at Bi(111) and pyrolytic graphite 
electrode surface. Tartu, 2016, 110 p. 
153.  Asko Laaniste. Comparison and optimisation of novel mass spectrometry 
ionisation sources. Tartu, 2016, 156 p. 
154.  Hanno Evard. Estimating limit of detection for mass spectrometric 
analysis methods. Tartu, 2016, 224 p. 
155. Kadri Ligi. Characterization and application of protein kinase-responsive  
organic probes with triplet-singlet energy transfer. Tartu, 2016, 122 p. 
156.  Margarita Kagan. Biosensing penicillins’ residues in milk flows. Tartu, 
2016, 130 p. 
157. Marie Kriisa. Development of protein kinase-responsive photolumine-
scent probes and cellular regulators of protein phosphorylation. Tartu, 
2016, 106 p. 
158. Mihkel Vestli. Ultrasonic spray pyrolysis deposited electrolyte layers for 
intermediate temperature solid oxide fuel cells. Tartu, 2016, 156 p. 
159. Silver Sepp. Influence of porosity of the carbide-derived carbon on the  
properties of the composite electrocatalysts and characteristics of polymer 
electrolyte fuel cells. Tartu, 2016, 137 p. 
160. Kristjan Haav. Quantitative relative equilibrium constant measurements 
in supramolecular chemistry. Tartu, 2017, 158 p. 
107 
161. Anu Teearu. Development of MALDI-FT-ICR-MS methodology for the 
analysis of resinous materials. Tartu, 2017, 205 p. 
162. Taavi Ivan. Bifunctional inhibitors and photoluminescent probes for 
studies on protein complexes. Tartu, 2017, 140 p. 
163. Maarja-Liisa Oldekop. Characterization of amino acid derivatization 
reagents for LC-MS analysis. Tartu, 2017, 147 p. 
164. Kristel Jukk. Electrochemical reduction of oxygen on platinum- and 
palladium-based nanocatalysts. Tartu, 2017, 250 p. 
165.  Siim Kukk. Kinetic aspects of interaction between dopamine transporter 
and N-substituted nortropane derivatives. Tartu, 2017, 107 p. 
166. Birgit Viira. Design and modelling in early drug development in 
targeting HIV-1 reverse transcriptase and Malaria. Tartu, 2017, 172 p. 
167. Rait Kivi. Allostery in cAMP dependent protein kinase catalytic subunit. 
Tartu, 2017, 115 p. 
168.  Agnes Heering. Experimental realization and applications of the unified 
acidity scale. Tartu, 2017, 123 p. 
169.  Delia Juronen. Biosensing system for the rapid multiplex detection of 
mastitis-causing pathogens in milk. Tartu, 2018,  85 p. 
170.  Hedi Rahnel. ARC-inhibitors: from reliable biochemical assays to regu-
lators of physiology of cells. Tartu, 2018, 176 p. 
171.  Anton Ruzanov. Computational investigation of the electrical double 
layer at metal–aqueous solution and metal–ionic liquid interfaces. Tartu, 
2018, 129 p. 
172.  Katrin Kestav. Crystal Structure-Guided Development of Bisubstrate-
Analogue Inhibitors of Mitotic Protein Kinase Haspin. Tartu, 2018, 166 p. 
173.  Mihkel Ilisson. Synthesis of novel heterocyclic hydrazine derivatives and 
their conjugates. Tartu, 2018, 101 p. 
174. Anni Allikalt. Development of assay systems for studying ligand binding 
to dopamine receptors. Tartu, 2018, 160 p. 
175. Ove Oll. Electrical double layer structure and energy storage characteris-
tics of ionic liquid based capacitors. Tartu, 2018, 187 p. 
176.  Rasmus Palm. Carbon materials for energy storage applications. Tartu, 
2018, 114 p. 
177. Jörgen Metsik. Preparation and stability of poly(3,4-ethylenedioxythio-
phene) thin films for transparent electrode applications. Tartu, 2018,  
111 p. 
178.  Sofja Tšepelevitš. Experimental studies and modeling of solute-solvent 
interactions. Tartu, 2018, 109 p. 
179. Märt Lõkov. Basicity of some nitrogen, phosphorus and carbon bases in 
acetonitrile. Tartu, 2018, 104 p. 
180. Anton Mastitski. Preparation of α-aza-amino acid precursors and related 
compounds by novel methods of reductive one-pot alkylation and direct 
alkylation. Tartu, 2018, 155 p. 
181.  Jürgen Vahter. Development of bisubstrate inhibitors for protein kinase 
CK2. Tartu, 2019, 186 p. 
182.  Piia Liigand. Expanding and improving methodology and applications of 
ionization efficiency measurements. Tartu, 2019, 189 p.  
183.  Sigrid Selberg. Synthesis and properties of lipophilic phosphazene-based 
indicator molecules. Tartu, 2019, 74 p.  
184. Jaanus Liigand. Standard substance free quantification for LC/ESI/MS 
analysis based on the predicted ionization efficiencies. Tartu, 2019, 254 p. 
185. Marek Mooste. Surface and electrochemical characterisation of aryl film 
and nanocomposite material modified carbon and metal-based electrodes. 
Tartu, 2019, 304 p.  
186. Mare Oja. Experimental investigation and modelling of pH profiles for 
effective membrane permeability of drug substances. Tartu, 2019, 306 p. 
187. Sajid Hussain. Electrochemical reduction of oxygen on supported Pt 
catalysts. Tartu, 2019, 220 p. 
188.  Ronald Väli. Glucose-derived hard carbon electrode materials for sodium-
ion batteries. Tartu, 2019, 180 p. 
189. Ester Tee. Analysis and development of selective synthesis methods of 
hierarchical micro- and mesoporous carbons. Tartu, 2019, 210 p. 
190. Martin Maide. Influence of the microstructure and chemical composition 
of the fuel electrode on the electrochemical performance of reversible 
solid oxide fuel cell. Tartu, 2020, 144 p. 
191. Edith Viirlaid. Biosensing Pesticides in Water Samples. Tartu, 2020, 102 p. 
192. Maike Käärik. Nanoporous carbon: the controlled nanostructure, and 
structure-property relationships. Tartu, 2020, 162 p. 
193.  Artur Gornischeff. Study of ionization efficiencies for derivatized com-
pounds in LC/ESI/MS and their application for targeted analysis. Tartu, 
2020, 124 p. 
